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Abstract 
Cell therapy, including human mesenchymal stem cell (hMSC) therapy, has the potential to treat 
different pathologies, including myocardial infarctions (heart attacks). Biological sutures composed of 
fibrin have been shown to effectively deliver hMSCs to infarcted hearts. However, hMSCs rapidly 
degrade fibrin making cell seeding and delivery time sensitive. To delay the degradation process, we 
propose using aprotinin, a proteolytic enzyme inhibitor that has been shown to slow fibrinolysis. This 
project investigated the effects of aprotinin on hMSCs and suture integrity. Viability of hMSCs incubated 
with aprotinin, examined using a LIVE/DEAD stain, was similar to controls. No differences in 
proliferation, as determined by Ki-67 presence, and were observed. hMSCs incubated in aprotinin 
differentiated into adipocytes, osteocytes, and chondrocytes, confirming multipotency.  CyQuant assays 
were used to determine the number of cells adhered to fibrin sutures.  The number of adhered cells was 
increased through aprotinin supplementation at Days 2, 3, and 5 time points. To examine the effect of 
aprotinin on suture integrity, sutures were loaded to failure to determine ultimate tensile strength (UTS) 
and modulus (E). Sutures exposed to aprotinin had higher UTS and E when compared to sutures exposed 
to standard growth media. Degradation of fibrin was quantified using an ELISA to quantify fibrin 
degradation products (FDP) and by measuring suture diameter. Fibrin sutures incubated in aprotinin had 
larger diameters and less FDP compared to the controls, confirming decreased fibrinolysis. These data 
suggest that aprotinin can reduce degradation of biological sutures, providing a novel method for 
extending the implantation window and increasing the number of cells delivered for hMSC seeded 
biological sutures.   
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Chapter 1: Introduction/Background 
 This project investigates the use of aprotinin as a novel method of extending the culture 
time of human mesenchymal stem cell (hMSC) seeded fibrin sutures for use in delivery to infarcted 
myocardium.  Previous work in the Gaudette lab indicates that fibrin sutures have the capacity to 
serve as a scaffold for hMSCs and are capable of cell delivery to infarcted myocardium [1].  This 
section will serve as a review of cardiac anatomy, the effects of infarction on healthy cardiac tissue, 
and a summary of current technologies aimed at the treatment of myocardial infarctions (MI).     
1.1 Myocardial Function and Infarcted Myocardium 
In the body, the heart acts as a pump circulating oxygen and nutrient rich blood to all parts 
of the body.  The mammalian heart consists of four chambers: the right atrium, the right ventricle, 
the left atrium, and the left ventricle, all of which are comprised of cardiac muscle or myocardium.  
The inner surface of the cardiac muscle is the endocardium while the exterior is known as the 
epicardium [2].  Deoxygenated blood from the body is received into the right atrium, which 
contracts and pumps blood to the right ventricle.  The right ventricle pumps deoxygenated blood to 
the lungs where the blood becomes oxygenated and then travels to the left atrium before being 
pushed into the left ventricle.  From the left ventricle, oxygenated blood is forced into the aorta and 
circulated throughout the whole body [3].  Because the left ventricle pumps blood to the whole 
body, it typically consists of the thickest muscle and exhibits the highest pressure.  Gap junctions 
allow the propagation of an action potential across the myocardium and create controlled 
contractions to effectively pump blood [4, 5].   
Coronary circulation provides nutrient and oxygen rich blood to the myocardium.  When a 
portion of coronary circulation is blocked, cardiomyocytes (muscle cells of the heart) become 
starved of oxygen and nutrients.  If this occurs there are several metabolic and physiological 
changes that occur [6, 7].  Without a continuous flow of oxygen and glucose to the myocardium, 
adenosine triphosphate (ATP) production switches from an aerobic pathway to an anaerobic 
pathway, which is much less efficient.  With less ATP available, contractions become weaker.  As 
creatine phosphate reserves become depleted, ATP production continues to slow.  If myocardial 
ischemia continues, an anaerobic respiration byproduct, hydrogen ions, accumulate and the 
intracellular pH decreases [6].  This leads to osmotic flooding of the myocytes and edema causing 
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permanent myocardium damage.  In the following weeks fibroblasts infiltrate the damaged area 
and begin depositing fibrous collagen.  Additionally, monocytes, neutrophils, and macrophages 
migrate to the infarction site as part of the inflammatory responses.  Neutrophils release matrix 
metalloproteinases (MMPs), causing further infarct expansion and myocyte collagen degradation 
[8]. 
Cardiovascular disease is currently the leading cause of death in the United States [9].  
Annually, approximately 920,000 people in the United States suffer from myocardial infarction, with 
coronary heart disease costing over $320 billion a year [10, 11].  MI can affect up to a billion heart 
cells, which decreases the workload of the heart [12].  Following a MI, in 2010 alone over one 
million patients were diagnosed with heart failure, meaning their heart is unable to sufficiently 
pump blood to the body’s organs.  Heart failure alters a patient’s ability to perform tasks requiring 
physical exertion or often even basic daily activities [13].  The number of deaths attributed to heart 
failure has remained relatively constant (approximately 287,000) between 1995 and 2011 [11].   
1.2 Clinical Treatments 
The heart has an extremely limited regenerative capacity and cannot repair itself following 
an MI, requiring medical intervention.  If an infarction is left untreated, remodeling can occur, 
changing the dimensions of the left ventricle and causing ventricular wall thinning [14].  The 
ejection fraction, or the fraction of blood contained within the left ventricle that is actually ejected 
with each heartbeat, declines with an increase in infarct size [14].  In an effort to maintain normal 
stroke volume and cardiac output, the contractile pattern and length of the uninfarcted zone 
changes, often called compensatory responses, and increases the risk of ventricular aneurysm and 
rupture [14]. 
Currently the treatment for MI is aimed at treating the effects of the infarction, not heal the 
underlying problem, the infarct zone.  Current treatments include cardiac bypass and ventricular 
remodeling.  Coronary bypass is a revascularization method used to restore essential blood flow to 
the myocardium [15].  Coronary artery bypass grafting (CABG) uses a blood vessel to divert blood 
around the infarction site and restore blood flow to the ischemic area, however this will not 
regenerate myocardial cells or restore function in the stiff collagenous region [15].  Reshaping the 
heart involves using one of two procedures: direct linear closure or endocardial patch plasty [16].  
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Direct linear closing removes the infarct and sutures the heart back together.  While this removes 
the infarct there may not be enough healthy myocardial tissue, depending on the size of the infarct, 
to effectively reconstruct the heart to proper dimensions [17].  If an infarct is too large to be safely 
removed, an endocentricular patch plasty is performed.  The patch can be synthetic or autologous 
tissue and is anchored to the ventricular wall.  This method surgically places a patch over the 
infarcted site and sutures the patch into place (infarct can also be removed and the patch is placed 
over the hole left by the removed infarct) [17]. 
Ventricular remodeling surgery is used to reshape the heart following a MI and the removal 
of the infarct.  A balloon is inflated within the left ventricle, showing the surgeon the initial shape 
and volume of the original heart.  While the infarct is removed this balloon aids the surgeon by 
providing a guide in restoring the heart to the original, more efficient shape.  The infarct is then 
removed.  A suture is placed around the incision site and tightened bringing the ventricle to the 
shape of the balloon. A synthetic patch is used to close any remaining gaps in the ventricular wall; 
this patch is made of either polyethylene terephthalate (PET, or commercially called Dacron) or 
polytetrafluoroethylene (PTFE).  The patch restores the volume of the ventricle and prevents 
shrinking of the heart [17, 18].  This surgical procedure restores the original dimensions of the heart 
and maintains pressure, but contractile tissue regeneration occurs.  PET and PTFE are inert and have 
mechanical properties much stronger than native cardiac tissue [19].  This leads to regions of 
fibrosis caused by the large difference in mechanical properties between the tissues and implant, 
similar to stress shielding; scar tissue formation still occurs and can still grow [19]. 
1.3 Cellular Therapies in Cardiac Regeneration 
Cellular therapies in cardiac regeneration are aimed at restoring the original function of 
cardiac tissue as opposed to removing the infarct.  Several cell types have been used in cellular 
therapies for restoring cardiac tissue, including bone marrow stem cells, skeletal myoblasts, 
embryonic stem cells, cardiac stem cells, and fetal cardiomyocytes [20-23].  Skeletal myoblasts will 
not electrically couple with myocardium tissue and have been known to cause fibrillation, 
embryonic stem cells have potential tumor formation, cardiac stem cells have controversial 
existence, and fetal cardiomyocytes cannot be obtained in sufficient numbers to be an effective 
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treatment [20-23].  This leaves bone marrow stem cells, specifically hMSCs a promising cell type for 
cardiac repair [24-26].  
1.3.1 Mesenchymal Stem Cells in Cardiac Repair 
Isolated from adult bone marrow, hMSCs are an adherent, multipotent cell type having the 
ability to differentiate into bone, cartilage, and fat.  hMSCs consist of between 0.001 to 0.01% of 
the nucleated cells within bone marrow [27, 28].  They have several characteristics which make 
them appealing in regenerative medicine.   These include relative ease of isolation, high expansion 
potential in-vitro, and genetic stability [27-29].  Specifically in cardiac regeneration, hMSCs can 
induce angiogenesis, be used allogenically without an immune response, and differentiate into 
cardiac myocyte-like phenotype [24, 28, 30].  hMSCs have been delivered to the heart and found to 
have improved cardiac function in terms of reduced infarction size and an increase in ventricular 
pressure [31-36].  
Table 1: MSCs in cellular therapies.   
Species Delivery Method 
Cell Population 
(and Quantity) 
Results Reference 
Rat IM 
Autologous MSCs 
(106): freshly 
isolated, 5-aza 
treated, untreated 
 Cellular engraftment at 
5 weeks 
 Increase in cardiac 
capillary density 
 LVSP and LVDP increase 
(5-aza) 
 Decrease: scar area and 
LV chamber size 
[37] 
Rat IM 
Autologous MSCs 
and CMEC (108) 
 Increase in cardiac 
capillary quantity and 
density 
 Increased myocardial 
perfusion 
 LVEF increase (45±2.2) 
[38] 
Rat IM 
Autologous MSCs 
(107) 
 Increase in capillary 
density 
 Increase in LVEF and 
perfusion to scarred 
region 
[39] 
Rat IM 
Autologous MSCs 
and peripheral 
blood 
 Increase in capillary 
density 
 LVD and LVEDV restored 
[40] 
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mononucleated 
cells (5*106) 
to baseline (MSC) 
 Increase in FS 
 Decrease in collagen 
deposition (MSC) 
Rat IM Allogenic MSC (107) 
 Increase in capillary 
density 
 Increase in LVSP and 
wall thickness 
 Decrease in LVEDP and 
infarct size 
[41] 
Rat IM 
Allogenic MSC, 
ASC, or AD-CMG 
(106) 
 Low engraftment at ASC 
and MSC at 1 week 
(none at 4 weeks) 
 Increase in capillary 
density 
 Increase in LVEF at 4 
weeks (ASC only) 
 Decrease in infarct size 
[42] 
Mouse IM 
Xenogenic MSC - 
human 
(5*105 or 1*106) 
 Majority of delivered 
cells in: spleen, liver, and 
lungs 
 Transplanted MSCs 
morphologically similar 
to native myocardium 
and express demsin, β-
myosin heavy chain, α-
actinin, cardiac troponin 
T, and phospholamban 
 Low engraftment (0.44% 
after 4 days) 
[30] 
Mouse IM 
Allogenic MSC 
(5*104 – 5*105) 
 Increase in LVDP 
 Decrease in LVEDP and 
infarct area 
[43] 
Mouse IM 
Allogenic MSC 
(5*104 – 5*105) 
 Engraftment at 2 weeks 
(not quantified) 
 New cardiomyocytes in 
infarcted area 
 Decrease in infarct size 
and fibrosis 
[44] 
Mouse IM 
Allogenic MSC 
(5*104) 
 Engraftment at 10 days 
(not quantified) 
 Increase in capillary 
density and number for 
arterioles 
 Decrease in LVEDP and 
infarct size 
[45] 
Mouse IM Allogenic MSC  Engraftment at 2 days [46] 
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(6*104) (25% of donor cells 
detected in border zone) 
 Gap junctions between 
donor cells and host 
cells 
 Restore contraction 
 Increase in LVDP and 
wall thickness 
 Decrease in LVEDP, scar 
formation, and chamber 
volume 
Pig IM 
Autologous MSC 
(6*107) 
 “Significant” 
engraftment (not 
quantified) 
 Preservation of wall 
thickness 
[47] 
Pig IM 
Allogenic MSC 
(2*108) 
 >50% MSC engraftment 
in 8 weeks 
 Decrease in infarct size 
 Increase in cardiac 
function 
 By 4 weeks myocardial 
efficacy returned to 
normal 
 Engrafted cells: express 
VEGF and VanWillebrand 
factor 
[48] 
Pig IC 
Autologous ASC or 
MSC (2*106) 
 Engraftment at 30 days 
(not quantified) 
 Increase in capillary 
density 
 Increase in LVEF and 
wall thickness (both 
groups) 
[49] 
Dog IM Allogenic MSC (108) 
 Increase in vascular 
density and LVEF 
 Decrease in collagen 
fibrosis 
[50] 
5-aza: 5-azacytidine, IM: intramyocardial, IC: intracoronary, LV: Left Ventricle, LVEDP: Left Ventricular End Diastolic Pressure, 
LVEDV: Left Ventricular End Diastolic Volume, LVEF: Left Ventricular Ejection Fraction, LVDP: Left Ventricular Developed 
Pressure, LVSP: Left Ventricular Systolic Pressure, LVD: Left Ventricular Dysfunction,  
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1.3.2 Myocardial Cellular Therapy Limitations 
As seen in Table 1, IM injections have been widely examined as a method for improvement 
in cardiac function following a MI.  There are several limitations associated with IM injections, 
including low cellular engraftment and retention, poor localization, low survival rates, and no matrix 
for cell adhesion, which often leads to cell death [12, 24-26, 51].   
In order for cellular therapies to provide any benefits, cells must be effectively delivered to 
the desired area.  Studies have investigated engraftment of hMSC following IM injections.  In a 
study performed by Hou et al, peripheral blood mononuclear cells were radiolabeled and delivered 
using the intramyocardial (IM), intracoronary (IC), or interstitial retrograde coronary venous (IRV) 
into a swine model.  Myocardial ischemia was induced using balloon occlusion for forty-five 
minutes.  107 111 indium-oxine–labeled human PBMNCs were delivered using IC, IM, or IRV 
injection after 6 days.  After cell delivery, animals were euthanized and organs were harvested for 
cell distribution assessment using γ-emission counting.  Upon investigation of the heart, a majority 
of the delivered cells were not retained by the heart (IM injection (11±3%), IC (2.6±0.3%), and IRV 
(3.2±1%) [52].  Many of these cells that were intended for delivery to the heart were in fact 
entrapped in other organs including the lungs, spleen, and liver [52]. 
  Another study performed by Guyette et al, used IM injections to delivery 100,000 hMSCs 
to infarcted rat hearts.  Following one hour after injection, hearts were fixed and sectioned to 
quantify the amount of engrafted hMSCs via quantum dots.  Rats that underwent IM injections had 
engraftment rates of 11.8 ± 6.2% [53].    
Injecting a liquid cellular suspension into contracting heart muscle resulted in a high 
percentage of cells leaking out of the heart, partially due to the heart’s contraction and the 
puncture hole created by the needle [12, 51].  A liquid suspension (Phosphate Buffered Solution 
(PBS) or media) is required to deliver cells via IM injection.  A liquid does not provide a matrix for 
cell attachment, which plays a role in cell death [25, 26, 54].   
15 
 
1.4 Fibrin Microthread Biological Sutures 
1.4.1 Fibrin Scaffolds and Tissue Engineering 
 Fibrin is a naturally occurring biopolymer and has been used as a biomaterial for tissue 
regeneration.  A series of coagulation reactions are triggered by platelet adhesion which occurs 
following an injury.  Platelet adhesion initiates the production of thrombin, a protease which 
cleaves fibrinogen.  Fibrinogen is a protein found in blood and when cleaved by thrombin fibrin 
forms.  Fibrin is an insoluble protein that stops bleeding at a  wound site and promotes healing [55].  
In the body, fibrin forms a provisional matrix that aids in the healing process by creating a scaffold 
for cell adhesion, migration, and infiltration [55].  Fibrin contains the protein sequence: arginine-
glycine-aspartic acid (RGD), this ligand binding motif promotes cell adhesion.  In addition to 
promoting cell adhesion, fibrin can be produced from autologous fibrinogen and thrombin, contains 
natural growth factors, is angiogenic, and is Food and Drug Administration (FDA) approved for 
clinical glues and sealants [56-58]. 
 Fibrin is a versatile biopolymer with a variety of uses in tissue engineering.   Fibrin hydrogels 
have been used in: adipose, cardiovascular, ocular, muscle, liver, skin, cartilage, neural, and bone 
applications [59].  These fibrin hydrogels can be composited with different plastics (polyurethanes, 
polycaprolactone-based polyurethanes, polycaprolactones, b-tricalciumphosphates, b-
tricalciumphosphates/ploycaprolactones, and polyethylene glycols), to create customizable properties 
(mechanicals, surface properties, or degradation) [59].  Fibrin glue is used as a sealant or a tissue 
adhesive, used in surgical procedures to reduce blood loss, accelerate healing, and protect against 
infection [60].  Fibrin glues can be sued as a delivery mechanism for cells or a scaffolding matrix [61-
63].  Fibrin glues have been used in maxillofacial bone, periodontal bone, bone, ear cartilage, cartilage, 
cornea, heart, blood vessel, tendon, and ligament regeneration, in addition to wound healing following 
severe burns and chronic wounds [59].  Fibrin scaffolds can be coated with extracellular matrix 
proteins, such as fibronectin, vitronectin, laminin, and collagen, to incorporate biological activity 
and cellular adhesion [64].   
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1.4.2 Fibrin Microthreads 
 A fibrin extrusion process has been developed at WPI [65].  Fibrinogen and thrombin are 
coextruded to form discrete fibrin threads. These threads are bunched and intertwined together 
forming bundles which are then made into sutures.  These sutures have been shown to an effective 
scaffold, allowing hMSC seeding on the sutures surface.  hMSCs delivered using fibrin microthread 
sutures exhibited an engraftment rate of 63.6 ± 10.6%, a significant increases when compared to 
the 11.8 ± 6.2% seen in the IM injection group [53].  In addition to the improved engraftment rate, 
fibrin sutures evoked a different delivery mechanism when compared to IM injections.  IM 
injections, involve a liquid being injected into the contracting heart muscle, which often has poor 
engraftment rate and a low percentage of hMSCs that remain in the heart [53].  The delivery of 
hMSC seeded sutures to the infarcted heart involves stitching the seeded fibrin directly into the 
infarcted region.  This delivers the hMSCs very specifically and to a more localized when compared 
to IM injections.   
 Despite having an improved engraftment and more localized delivery, there is a low initial 
seeded.  100,000 cells are seeded on the fibrin sutures, however after twenty four hours of seeding, 
less than 10,000 hMSCs adhere to sutures [66].  There are two methods to increase the number of 
cells that are adhered to cells (excluding coating sutures with adhesion proteins): increasing the 
seeding density, and increasing the culture time.  Increasing the seeding density with introduce 
more cells to the 24 hour seeding period.  If the adhesion percentage remains the same, there are 
still a high number of cells that are being wasted, not adhering to the suture.  The large number of 
cells that would be wasted makes this an unfavorable approach.  Increasing the culture time would 
allow hMSCs to proliferate on the suture, leading to more hMSCs on the suture.  The problem with 
this approach is that hMSCs secrete fibrinolytic enzymes [67].  The longer the hMSCs are cultured 
the more of the suture degrades, creating a weaker suture that will not have the mechanical 
strength to suture through the heart and deliver hMSCs.     
1.4.2 Degradation of Fibrin 
Fibrinolysis, or the breakdown of fibrin, is a heavily regulated by numerous receptors, 
cofactors, inhibitors, activators, and substrates [68].  The components of fibrinolysis of are listed in 
Table 2 and illustrated in Figure 1.   
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Table 2: Components of fibrinolysis  
Zymogen 
Plasminogen 
activators 
Inhibitors Attenuator 
Major 
Receptors - 
Activating 
Major Receptors - 
Clearance 
Plasminogen 
(N-terminal 
glutamic acid 
and lysine 
variants) 
Tissue 
plasminogen 
activator  
(tPA) 
Plasmin 
inhibitors 
Thrombin-
activatable 
fibrinolysis 
inhibitor  
(TAFI) 
Annexin 2 
 
 
Low-density 
lipoprotein 
receptor-related 
protein  
(LRP) 
 
α2-plasmin 
inhibitor 
 (α2-PI) 
α2-
macroglobulin 
(α2-MG) 
Protease nexin 
αMβ2 integrin 
Urokinase 
(uPA) 
Plasminogen 
activator 
inhibitors 
Mannose receptor 
Plasminogen 
activator 
inhibitor-1 & -2 
(PAI-1, PAI-2) 
C1-esterase 
inhibitor Urokinase 
receptor 
(uPAR) 
Protease nexin 
Plasmin 
inhibitors 
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Figure 1: Fibrinolysis Pathway.  Red arrows indicate activation.  Blue arrows indicate inhibition.   
(Image adapted from cri.sagepub.com/content/15/5/188/F1.large.jpg) 
 
Plasmin is one the primary fibrinolytic proteases in vivo.  A zymogen found naturally 
circulating in blood; plasminogen (PLG) can be cleaved and converted to plasmin by tissue 
plasminogen activator (tPA) or urokinase plasminogen activator (uPA).  Plasmin is also involved in a 
positive feedback mechanism, deactivating tPA and uPA.  Fibrin regulates its degradation by actively 
binding to PLG and tPA, which localizes and enhances plasmin generation in close proximity to 
fibrin.  When unbound to fibrin, tPA is a weak activator of PLG, but in the presence of fibrin, the 
binding affinity and activation are greatly enhanced [68].   
Plasmin cleaves fibrin into soluble fibrin degradation products (FDP).  During degradation, 
carboxy-terminal lysine residues are exposed, further enhancing binding to the lysine binding sites 
of tPA and PLG.  The lysine binding sites can be blocked by thrombin-activatable fibrinolysis 
inhibitor (TAFI), which in turn decreases plasmin generation and slows fibrinolysis.  Fibrinolysis is 
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also regulated by PLG activation inhibitors (PLG activator inhibitor-1 (PAI-1)) and plasma inhibitors 
(α2-plasmin inhibitor (α2-PI)).  However, because fibrin bound plasmin has lysine binding sites are 
occupied; it is blocked from α2-PI [68].  Cells can also promote plasmin formation by surface 
receptors.  Endothelial cells, monocytes, macrophages, neutrophils, and some tumorigenic cells 
have been shown to bind to PLG, tPA, or uPA [69].   
hMSCs are important in the wound healing process and have been shown to express PLG, 
uPA, tPA, and PAI.  This indicates that hMSCs can regulate and control fibrinolysis in both autocrine 
and paracrine mechanisms.  A study by Neuss et al, investigated the fibrin degradation by hMSCs.  
They found that when hMSCs were seeded in fibrin clots, the hMSCs could degrade fibrin clots as 
indicated by amounts of the fibrin degradation product, D-dimer, found in solution.  The entrapped 
hMSCs released fibrinolytic enzymes that triggered fibrin degradation.  It was also observed that 
fibroblasts produced similar amounts of D-dimers as fibroblasts trapped in fibrin clots [67].    
1.4.3 Aprotinin 
Aprotinin (C284H432N84O79S7), known as the drug Trasylol, is protease inhibitor isolated from 
bovine lung.  Aprotinin is a monomeric globular polypeptide chain.  With a molecular weight of 
6512, aprotinin is 58 residues long, consisting of 16 different proteins, shown in Figure 2 [70].  Three 
disulfide bonds, a β-hairpin, and an alpha helix describe the tertiary structure of aprotinin [71].  The 
specific amino acid sequence for aprotinin is as follows: RPDFC LEPPY TGPCK ARIIR YFYNA KAGLC 
QTFVY GGCRA KRNNF KSAED CMRTC GGA [72].  Positive charged side chains (lysine-K and arginine-
R) outnumber the negative side chains (aspartate-D and glutamates-E) 10 to 4, making aprotinin 
basic in solution.  The three disulfide bonds between cysteine proteins (specifically at: Cys5-Cys55, 
Cys14-Cys38 and Cys30-Cys51) make aprotinin highly stable [72].  One of the basic side chains (the 
15-lysine) binds to active sites and inhibits trypsin and similar proteases.  At pHs above 10 and 
below 3.2, aprotinin is inactive as a result of aprotinin-protease complex dissociation.  Reactivity of 
protease inhibitors are measured in units of Trypsin Inhibitor Units (TIU).  1TIU will decrease the 
activity of 2 trypsin units by 50%, where the 1 trypsin until will hydrolyze 1.0 µmole of N-α-benzoyl-
DL-arginine p-nitroanilide (BAPNA) per minute at pH 7.8 and 25 °C.  Another common unit of 
activity is the inhibition of kallikreins, the kallikrein inhibitor unit (KIU).  Similar to TIU, one KIU will 
inhibit 2 kallikrein units by 50% at pH 7.8 and 25 °C.  1 TIU is equal to approximately 1,025 KIU [73].  
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Aprotinin inhibits trypsin, chymotrypsin, and plasmin at a concentration of 125,000 IU/mL and 
Kallikrein at 300,000 IU/mL.   
 
Figure 2: Aprotinin. 58 residues long with 3 disulfide bridges. (Image from Sigma-Aldrich information packet on Aprotinin) 
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Aprotinin, or Trasylol, was used in patients with an increased risk for blood loss, especially 
during CABG surgeries or any surgery with the need for blood transfusions.  A study in 2006, 
studying the effects of aprotinin on cardiac surgery patients revealed that there was an increase in 
the risk of: acute renal failure, myocardial infarction, heart failure, stroke, and encephalopathy [74].  
These results were exhibited again in 2007 [75].  Aprotinin was removed from clinical use in 2008, 
following the previously mentioned studies that suggested an increase in complications and death 
with aprotinin use [76].  However, in 2012 the European Medicines Agency scientific committee 
performed a full review of the “Blood conservation using antifibrinolytics” (BART) investigation of 
aprotinin.  The committee found the BART study was skewed and the results were not indicative of 
the actual results.  The investigation found that the benefits of the use of antifibrinolytic medicines, 
including aprotinin, outweigh the risks in a restricted range of indications and the suspension on 
aprotinin was lifted [77].    
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Chapter 2: Hypothesis and Specific Aims 
We hypothesize that supplementing hMSC growth media with aprotinin will slow the 
degradation of hMSC seeded fibrin sutures.  With a decrease in scaffold degradation, sutures will be 
able to be cultured for extended periods of time, without a loss of mechanical integrity.   
Specific Aim 1: Examine the effect of aprotinin on cell-loaded sutures, in terms of suture 
degradation and suture mechanics 
If aprotinin slows down the degradation of fibrin sutures, the amount of fibrin degradation 
products found in media will be decreased in sutures exposed to aprotinin.  Using a range of 
concentrations of aprotinin: 0, 1, 5, 10, 50, and 100 µg per mL of standard mesenchymal stem cell 
growth media; the amount of fibrin degradation products will be quantified at Days 3, 6, and 9. An 
ELISA assay will be used to quantify the concentration of fibrin degradation products present in the 
media at each time point.  The Elastic Modulus, Ultimate Tensile Strength, and Strain At Failure will 
be used to assess the mechanical properties after cells have been seeded for 24 hours and cultured 
for 3 days.  Suture diameter will also be used to determine suture degradation.   
Specific Aim 2: Determine the effect of aprotinin on hMSC viability, proliferation, and 
differentiation capacity  
In order to aprotinin in an attempt to control suture degradation, it must not affect hMSC 
viability.  To determine the effect of aprotinin on hMSC viability, hMSCs will be seeded and cultured 
on glass coverslips for one week before undergoing a LIVE/DEAD assay to determine the percentage 
of live cells.  To examine cellular proliferation a stain for Ki-67 will be used to ensure aprotinin is not 
negatively effecting hMSC proliferation.  hMSCs will be seeded on glass coverslips and cultured for 
three days, to ensure that confluence is not reached and proliferation decreases.  hMSCs are 
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multipotent cells and aprotinin must not effect hMSC multipotency in order to be an effective 
method to reduce fibrin degradation.  A differentiation assay will be used to determine the effect, if 
any, aprotinin has on hMSC differentiation.  hMSCs will be differentiated into: adipocytes, 
chondrocytes, and osteocytes, after exposure to wither standard growth media or aprotinin 
supplemented growth media.   
Specific Aim 3: Determine the effect of aprotinin on cell quantity on cell loaded sutures 
 For aprotinin to be useful, it must not negatively affect hMSCs loaded on fibrin based 
sutures.  hMSCs will be seeded on fibrin sutures for twenty-four hours.  The number of cells 
adhered to the sutures will be examined at Days 0 (immediately following the twenty-four hour 
seeding), 1, 2, 3, and 5.  The number of cells remaining on the fibrin sutures will be determined via 
CyQuant Assays.     
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Chapter 3: Materials and Methods 
3.1 Fibrin Microthread and Suture Production 
Fibrin microthreads were coextruded using solutions of fibrinogen and thrombin, in a 
manner previously described [65].  In brief, thrombin isolated from bovine plasma (Sigma, St. Louis, 
MO T4648) at a concentration of 40 U/ml was frozen at -20oC as a stock solution; and diluted to a 
concentration of 6 U/ml in 40 mM CaCl2 for extrusion.  Fibrinogen (Sigma, St. Louis, MO F4753) was 
dissolved in HEPES buffered saline (HBS, 20 mM HEPES, 0.9% NaCl) at a concentration of 70 mg/mL 
and stored at -20oC.  Fibrinogen and thrombin were warmed to 37oC and drawn up into two 
separate 1mL syringes.  The fibrinogen and thrombin solutions were mixed in a blending applicator 
tip and coextruded through polyethylene tubing (0.38mm inner diameter, Beckton Dickinson, 
Franklin Lakes, NJ) at a crosshead speed of 4.25 mm/min.  The polyethylene tubing extended into a 
bath of room temperature 10 mM HEPES at a pH of 7.4 (Figure 3).  After fifteen minutes, the fibrin 
microthreads were removed from the bath and hung to air dry.   
 
Figure 3: Fibrin microthread extrusion schematic and image of extruded threads [59]. 
To increase the mechanical properties of the fibrin microthreads and increase the area for 
cellular adhesion, several microthreads were bundled together to form a single large diameter 
microthread, as seen in Figure 4.  Twelve microthreads were placed parallel to each other and 
grouped together by dragging a droplet of PBS along the threads.  Once the twelve microthreads 
were grouped together the bundle was twisted to form an entwined bundle.   
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Figure 4:  Microthreads to bundles.  Using a drop of PBS, 12 separate fibrin microthreads are brought together 
and twisted to form a single bundle of 12 fibrin microthreads. 
Microthread bundles were cut 4 cm lengths (8 cm lengths were used for mechanical 
testing), shown in Figure 5.  Each cut microthread bundle was threaded through the eye of a 
surgical suture needle (size #20, 3/800 circle, tapered; Securos Surgical, Fiskdale, MA).  With the 
needle placed in the center of the bundle, the bundle was hydrated for twenty minutes in DI water.  
After hydration the ends of the bundle were folded together, twisted, and dried to form a 2 cm 
suture (4 cm for mechanical testing) of twenty-four microthreads.   
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Figure 5:  Suture Fabrication.  12 bundles of fibrin microthreads are cut to 4 cm, placed through the eye of a 
suture needle, hydrated in DI water, and twisted forming a 2 cm long suture. 
To seed the sutures with cells a bioreactor was constructed around each suture, seen in 
Figure 6.  A section of gas-permeable Silastic tubing (1.98-mm ID, Dow Corning, Midland, MI) 
approximately double the length of the suture was used to house the fibrin suture.  A slide clamp 
was used to secure a 27-gaugue needle and the suture needle inside the bioreactor tubing and 
sterilized using a twelve hour cycle of ethylene oxide gas. 
 
Figure 6: Suture housed inside bioreactor.  Gas permeable polyethylene tubing is used to allow ethylene oxide 
sterilization to occur and to allow gas exchange when cells being seeded, the 27 Gauge syringe needle is used to 
deliver hMSCs, and the slide clamps holds the cellular suspension in the bioreactor. 
After sterilization, the sutures were rehydrated in sterile Dulnecco’s Phosphate Buffered 
Saline (DPBS, Mediatech Inc, Manassas VA) for twenty minutes.  Sutures were seeded with a cellular 
suspension concentration of 1x106 cells/mL and at 50,000 cells per 1 cm of suture.  100 µL of the 
cellular suspension was drawn up into a 1 mL syringe.  The syringe, containing the cellular 
suspension, was attached to the 27 gauge needle of the bioreactor and used to inject the cellular 
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suspension.  Bioreactors were then loaded into vented 50 mL conical tubes and placed on a rotator 
in a 37OC incubator (5% CO2, atmospheric gas concentrations).  Sutures were seeded for 24 hours. 
Human mesenchymal stem cells (hMSCs; Lonza, Walkersville, MD; passage 5-8) were 
cultured in Mesenchymal Stem Cell Growth Medium (MSCGM; Lonza PT-3001, Walkersville, MD) in 
compliance with the manufacturer’s instructions.  Aprotinin was supplemented to complete 
MSCGM at a concentration of 100 µg/ml.  Aprotinin supplemented media will be referred to as 
“Aprotinin” for the remainder of this paper, the concentration of aprotinin in MSCGM will be 100 
µg/ml unless otherwise noted.  This stock media was frozen in 10 mL aliquots and thawed as 
needed.  After it was thawed it was used in less than two weeks; after this thaw media was not 
refrozen.   
3.2 Preliminary Fibrin Degradation 
Sutures (Aprotinin n=3 and MSCGM n=3) were seeded in a manner previously described.  
After seeding for 24 hours, sutures were plated in individual wells of a 12 well plate with 1 ml of 
either Aprotinin or MSCGM.  Sutures were not disturbed.  Media changes occurred every three days 
and light media swirling occurred every day.  Sutures were not removed from the wells.  Media 
changes took place until threads were degraded.   
3.3 Fibrin Degradation Product ELISA 
An FDP ELISA kit (NeoBioLab, Cambridge, MA) was used to determine the amount of FDP 
present in media used to culture seeded sutures.  Sutures were created and seeded in the manner 
previously described.  After cells were seeded, sutures were placed in wells of a twelve well plate 
and cultured in the following concentrations of aprotinin in MSCGM: 100, 50, 10, 5, 1 and 0 µg of 
aprotinin per mL of MSCGM (Aprotinin-100,-50,-10,-5,-1, and MSCGM, respectively), with controls 
being unseeded sutures in PBS, MSCGM, and Aprotinin-100.  Media changes occurred every 3 days 
for 9 days.  Media was removed and placed in 2 ml Eppendorf tubes and stored at -80⁰C until all 
samples were collected.  Sample and components of the FDP ELISA were allowed to thaw to room 
temperature.  100 µL of samples were added to wells of the ninety-six well microtiter plate and 10 
µL of balance solution was added to each.  The FDP ELISA kit includes dilutions of FDP, in order to 
create a standard curve, which were also placed in the microtiter plate; these dilutions were: 0, 0.5, 
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1, 2.5, 5, and 10 mg/mL.  50 µL of conjugate was added to well with samples or standards, and 
mixed well.  After mixing, the plate was covered and incubated at 37⁰C for 1 hour.  Wells were 
washed 5 times with 300 µL of wash solution and blotted dry.  50 µL of Substrates A and B were 
added to wells containing samples or standards.  The plate was covered and incubated at room 
temperature for 15 minutes.  50 µL of stop solution was mixed into each well.  The optical density 
(OD) at 450 nm was then measured on a Victor3 1420 Plate Reader.   
A standard curve was created by plotting the optical densities of the included standards 
against the concentration of FDP.  A best fit line was created in order to determine the 
concentration of FDP in the collected samples.    
3.4 Suture Mechanics 
4 cm sutures were seeding with 200,000 hMSCs per suture, in the manner previously 
described.  After seeding, the sutures were plated in separate wells of a six well plate with 3 mL of 
either MSCGM or Aprotinin.  After three days, sutures were removed from the media for diameter 
measurements and mechanical testing.  Three days was used as the end point because after three 
days of culture, there is no significant increase in the number of cells on the suture (16), and after 
three days, the control sutures had little to no mechanical integrity and could not be loaded for 
mechanical testing.  These sutures often broke while loading sutures into the Instron grips.  Sutures 
were removed from media and rinsed and store in PBS until diameter measurement and 
mechanical testing the same day.  Test groups for thread diameters and mechanical testing 
included: MSCGM, Aprotinin, MSCGM with no cells, Aprotinin with no cells, and sutures hydrated in 
PBS for twenty minutes. 
3.4.1 Thread diameters 
Before mechanical testing, sutures were placed on a glass slide and three images were 
acquired on Leica DM LB2 microscope at 5 x.  Suture diameters were measured with no coverslip on 
top of the suture.  Because the sutures are two bundles twisted together there is a large difference 
in diameter when looking at the threads on a two dimensional plane.  In order to get a 
representative diameter over the 4 cm of the suture, three images were taken of each suture: one 
at the left end (in the first cm of the thread, proximal to the needle), center (approximately 2 cm 
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from the needle), and the right end (at the end of the thread distal to the needle).  For each image 
the maximum and the minimum diameters were recorded.  The average suture diameter 
determined by taking the average of the six diameters obtained for each suture. 
3.4.2 Mechanical Testing 
Mechanical testing was performed on an Instron E1000, using a 1N load cell.  Sutures were 
secured in custom grips and loaded onto the Instron.  Once loaded on the Instron, the sutures were 
hydrated using PBS from a dropper a final time before testing.  A 10 mN load was applied to the 
sutures, and a ruler was used measure the distance between the grips (this value was used as the 
initial length of the suture).  Using Bluehill software, a tensile test to failure was performed on each 
suture.  The data output by BlueHill was in Force (N)/Displacement (mm).  Using the average suture 
diameter and the gauge length, the Force-Displacement data was converted to Stress/Strain and 
plotted.  From the Stress-Strain curve the Ultimate Tensile Strength (UTS), Modulus (E), and Strain 
at Failure (SAF) was calculated.    
3.5 Cell Viability 
To confirm hMSC viability, a LIVE/DEAD Viability/Cytoxicity Kit for mammalian cells 
(Invitrogen L-3244, Carlsbad, CA) was used.  This kit uses two stains, calcein and ethidium.  Calcein is 
absorbed by cells and fluoresces green when intracellular esterase activity occurs; which only 
occurs in live cells.  Ethidium penetrates the nuclei of dead cells; and binds to nucleic acids, 
fluorescing red.   Hoechst was used as a nuclei stain to identify cells.   
hMSCs were seeded on glass coverslips at a seeding density of approximately 5000 
cells/cm2.  Six coverslips were cultured in MSCGM and six were cultured in MSCGM or Aprotinin.  
Media was changed every 3 days until confluence was reached; this occurred in approximately 
seven days.   
After the hMSCs on the coverslips had reached confluence, they were rinsed in PBS and 
incubated at 37OC with a 1:1000 dilution of ethidum, 1:1000 dilution of calcein, and a 1:2000 
dilution of Hoechst for 30 minutes.  The coverslips were mounted on glass slides using Cytoseal, and 
images using a Leica DM LB2 microscope at 20x magnification.  Images were acquired using a blue, 
red, and green fluorescent channels to acquire the hMSC nuclei, dead cells, and live cells, 
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respectively.  Two sets of images were acquired from each coverslip and the average numbers of 
live and dead cells were determined.    
Images were imported into ImageJ to quantify the numbers of live and dead cells.  Using the 
blue channel, the Hoechst stain, the image was split into red, blue, and green channels; and the 
blue channel was thresholded until only the nuclei remained.  From there the nuclei were counted 
using the Particle Analysis function on ImageJ, indicating the total number of cells.  This was 
repeated for the ethidium and calcein stained images to determine the number of dead and live 
cells, respectively.   
3.6 Ki-67 Proliferation 
To determine if aprotinin affected hMSC growth a stain for Ki-67 was used.  Ki-67 is a 
protein expressed during cellular proliferation, specifically during the G1, S, G2, and M phases.  
hMSCs were seeded on glass coverslips at a seeding density of approximately 5000 cells/cm2.  Six 
coverslips were cultured in MSCGM and 6 were cultured in Aprotinin. 
After three days, the cover slips were rinsed with PBS, fixed for fifteen minutes in 4% 
paraformaldehyde in PBS, and then rinsed again with PBS.  0.25% Triton-X100 in DI water was used 
to permeabilize hMSCs for twenty minutes.  After permeabilization, the coverslips were rinsed with 
PBS and blocked with 5% goat serum in PBS for thirty minutes.  Coverslips were incubated at 4⁰C 
with rabbit anti Ki-67 monoclonal at a dilution of 1:100 (Sigma,AB1667) in 3% goat serum in PBS for 
10 hours, then rinsed in PBS.  Alexa-fluor 568 goat anti-rabbit at a dilution of 1:400 (Invitrogen 
A11036) in 3% goat serum in PBS was used as the secondary antibody and incubated at room 
temperature for one hour.  The coverslips were rinsed with PBS then counterstained with Hoechst 
at a concentration of 1:6000 for five minutes.  Coverslips were again rinsed in PBS and mounted 
using Cytoseal.  Fluorescent images were acquired using a Leica DM LB2 microscope.  Two images 
were acquired from each coverslip and the average numbers of Ki-67 positive cells were counted. 
The same thresholding technique used for the LIVE/DEAD analysis was used for determining 
the percent of Ki-67 positive cells.  The Hoechst stain, viewed through the blue channel, was used to 
determine the number of cells.  The Hoechst stained image was split into red, blue, and green 
channels.  The blue channel was thresholded until only the nuclei remained and the remaining 
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nuclei were counted using the Particle Analysis function on ImageJ.  This process was repeated on 
the Ki-67 stained image, which was taken using the red fluorescent cube on the Leica DM LB2 
microscope.  This image was split into the red, blue, and green channels, and the red was 
thresholded and analyzed, determining the number of Ki-67 positive cells.   
3.7 Differentiation Assay 
hMSCs are multipotent cells, meaning they have the ability to differentiate into multiple 
cells types.  To ensure that aprotinin does not hinder the multipotency capacity of hMSCs a 
differentiation assay was performed.  hMSCs were differentiated into the following three cell types: 
adipogenic, osteogenic, and chondrogenic.   
3.7.1 Adipogenic Differentiation 
For adipogenic differentiation, hMSCs were seeded at 5000 cells/cm2 in 12 well plates and 
cultured in either MSCGM or Aprotinin.  Media changes occurred every 3 days until cells were 100% 
confluence.   
Adipogenic differentiation was completed using adipogenic kit from Lonza (Adipogenic 
Differentiation Medium, PT-3004).  hMSCs were fed for three cycles of three days with Adipogenic 
Induction Medium followed by three days with Adipogenic Maintenance Medium.  After the three 
cycles of Maintenance and Induction media, all cells were cultured for an additional cycle in 
Adipogenic Maintenance Medium.  hMSCs were differentiated in three separate experiments with n 
= 3 in each experiment.  The control group for adipogenic differentiation was n = 3 wells of a twelve 
well plate, grown to confluence in either Aprotinin or MSCGM. 
3.7.2 Oil Red O Stain 
To assess lipid vacuole formation, adipogenic cells were stained with Oil Red O.  Cells were 
fixed using 4% paraformaldehyde in PBS for fifteen minutes, rinsed in distilled water for five 
minutes then dehydrated in 60% isopropanol for five minutes.  300 mg of Oil Red powder (Sigma 
Aldrich, St. Louis, MO) was dissolved into 100 mL of 100% isopropanol to make the Oil Red O stock 
solution.  To create the working solution, three parts of the stock solution were combined with two 
parts of a 10% Dextrin-DI solution; then filtered using a 0.80 µm membrane syringe filter (Corning 
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Incorporated, Corning, NY).  Cell cultures were stained with the Oil Red O working solution for five 
minutes and counterstained with Mayer’s hematoxylin (Sigma Aldrich, St. Louis, MO) for one 
minute before rinsing with DI water.  Stained images were acquired with a LEICA DMIL microscope. 
3.7.3 Osteogenic Differentiation 
hMSCs were seeded at 5000 cells/cm2 in twelve well plates and cultured in either MSCGM 
or Aprotinin.  Media changes occurred every three days until cells were 100% confluence.  Cells 
were then fed Complete Osteogenic Differentiation Media (Lonza, Walkersville, MD).  Media 
changes occurred every three days for three weeks.  Over the course of the osteogenic 
differentiation, cells were observed under a LEICA DMIL microscope to confirm changes in cell 
morphology from spindle to cuboidal shaped.  hMSCs were differentiated in three separate 
experiments with n = 3 in each experiment.  The control group for osteogenic differentiation was 
n=3 wells of a twelve well plate, grown to confluence in either Aprotinin or MSCGM. 
3.7.4 Alizarin Red S Stain 
Alizarin Red S was used to assess calcium deposits.  Cells were first rinsed with calcium free 
PBS (Invitrogen, Carlsbad, CA) for one minute and fixed in 4% paraformaldehyde in PBS for fifteen 
minutes.  After fixing cultures were rinsed with PBS and DI water for 5 minutes each.  The Alizarin 
Red stock solution was made by dissolving 2 grams of Alizarin Red Powder into 100 mL of DI water.  
The pH of the stock solution was adjusted to 4.1-4.3 using 10% ammonium hydroxide.  Cultures 
were stained with Alizarin Red S working solution for five minutes then rinsed with DI water for five 
minutes.  Osteocytes were imaged using a LEICA DMIL microscope after rinsing. 
3.7.5 Chondrogenic Differentiation   
hMSCs were cultures in t75s and media was changed every three days until confluence was 
reached.  Once confluence was reached, cells were passaged placed into 15 mL conical tubes at 
250,000 cells per.  Cells were washed in incomplete chondrogenic media, by resuspending and 
centrifuging at 150G for five minutes.  Complete condrogenic media was created by adding TGF-β3 
(Lonza, Walkersville, MD) to incomplete condrogenic media (Lonza, Walkersville, MD).  Cells were 
resuspended in 5 mL of complete condrogenic media and centrifuged at 150G for five minutes.  The 
conical tube was incubated at 37°C, in a humidified atmosphere of 5% CO2, with the cap of the 
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conical tube was not fully tightened to allow gas exchange.  Media changes occurred every three 
days and after media change, ensure that the pellet is free-floating.  Chondrocyte pellets were 
harvested after twenty days for sectioning.  hMSCs were differentiated in three separate 
experiments with n = 3 in each experiment.   
Chondrocyte pellets were fixed for three minutes in 4% paraformaldehyde in PBS, and 
rinsed in PBS before and after fixing.  Pellets were prepped for section using an Automated Tissue 
Processor, on a delicate, no fix cycle.  A 2 w/w% agarose gel was prepared using and heated using a 
hot plate until the solution of 1 gram of agarose into 49 grams of water, melted and dissolved.  The 
melted agarose solution was poured over the chondrocyte pellet and placed cooled to 20⁰C to 
solidify the agarose solution.  The chondrocyte pellet was then embedded in paraffin and sectioned 
using a LIECA RM 2235 microtome, cutting 5 µm sections and fixed to charged glass slides.   
3.7.6 Masson’s Trichrome  
Chondrogenic pellet sections were stained using Masson’s Trichrome to detect Collagen II, 
produced by chondrocytes.  Paraffin sections were first deparaffinized in: Xylene I, Xylene II, Xylene 
III, 100% EtOH, 95% EtOH, and 70% EtOH for three minutes each.  Slides were then rinsed in running 
water for 10 minutes.  Sections were mordanted in Bouin’s solution (sigma HT10-1-128) for one 
hour at 60⁰C then rinsed in running water for ten minutes.  Weigert’s hematoxylin, created by 
mixing equal parts of Solution A (sigma HT107-500mL) and Solution B (sigma HT109-500mL), was 
used to stain sections for ten minutes.  Sections were rinsed with running water for ten minutes. 
Sections were stained for five minutes using a working Biebrich Scarlet-Acid Fuchsin Solution (1 
gram of Biebrich Scarlett, 1 gram of Acid Fuchsin, and 198 mL of DI water), then rinsed for ten 
minutes in running water.  Slides were then placed in Phosphomolybdic/phosphotungstic acid 
solution (1 Part Phosphomolybdic acid solution (HT156-250 mL), 1 Part Phosphotungstic acid 
solution (HT152-250 mL), and 2 Parts DI Water) for fifteen minutes.  Slides were immediately 
stained in aniline blue solution (Aniline Blue 5g, 100% Glacial Acetic Acid 4 mL, and DI water 200 
mL) for five minutes followed by a rinse in running water for two minutes.  Slides were then placed 
in 1% acetic acid solution for five minutes.  Sectioned chondrocytes were then dehydrated: in two, 
one minutes cycles in 95% EtOH; two, one minute cycles in 100% EtOH; one, five minute cycle in 
100% EtOH; one, five minute cycle in Xylene IV; and one, five minute cycle in Xylene V.  Following 
34 
 
dehydration, slides were mounted in cytoseal and coversliped and imaged using a Leica DM LB2 
microscope.  Masson’s Trichrome stains Nuclei – black, collagen – blue, and cytoplasm and keratin – 
red.   
3.7.7 Picro-sirius Stain 
In addition to the Masson’s Trichrome, a Picro-sirius Stain was used to identify collagen.  After 
chondrocytes were paraffin embedded, sectioned 5 µm  sections), and adhered to slides, deparaffinized 
in: Xylene I, Xylene II, Xylene III, 100% EtOH, 100% EtOH, and 90% EtOH for 2 minutes each, then 
placed in running water for five minutes.  Slides were then stained in Harris Hematoxylin for two 
minutes and rinsed in running water for two minutes.  A quick dip in acid alcohol, a quick rinse in 
water, and a dip in ammonia water (approximately thirty seconds) was completed before a rinse in 
tap water for ten minutes.  Slides are then exposed to Picro-Sirius Red fast green for thirty minutes.  
The Picro-Sirius Red fast green is made by mixing 0.03 grams of Fast Green in 100 mL of Picric Acid.  
Slides are then dehydrated using: 80% EtOH (one minute), 95% EtOH (one minute), 95% EtOH (one 
minute), 100 % EtOH (one minute), 100% EtOH (five minutes), Xylene IV (two minutes), and Xylene 
V (five minutes).  
3.8 CyQuant Assay 
The CyQuant cell proliferation assay kit (Molecular Probes, Eugene, OR) uses a DNA stain to 
fluorescently label DNA and using a standard curve correlates the fluoresced DNA to a number of 
cells.  To create the CyQuant lysis buffer used in the assay, 1 mL of Cell-lysis buffer and 50 µL of 
CyQuant GR fluorescent dye were added to 19 mL of DPBS.   
Sutures were created, seeded, and sterilized in the manner previously described.  After 
seeding the sutures were removed from the bioreactors and cut to 1 cm to standardize the length 
of sutures.  Sutures were then placed in microcentrifuge tube with 500 µL of DPBS and centrifuged 
for 5 minutes at 2,000 RPM.  After centrifuging, 400 µL of DPBS was removed and samples were 
placed in - 80⁰C.  The deionized water of the DPBS freezes and lyses the cells leaving the DNA in 
solution.  After at least one hour at - 80⁰C, samples were brought to room temperature.  
Using a flat bottomed 96 well plate, 100 µL of the CyQuant lysis buffer were added to wells 
in Columns 1-4 and Rows B-H.  In row A, columns 1-4, 30,000 hMSCs were added in 200 µL of DPBS.   
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Immediately afterwards, 100 µL was transferred from row A to row B, then from row B to row 
C…until row G, ensuing that each was thoroughly mixed.  In columns 1-4 in row, H an additional 100 
µL of CyQuant lysis buffer was added.  Row H contained no cells served as blanks for the standard 
curve.   
CyQuant lysis buffer was added at a volume of 400 µL to microcentrifuge tubes containing 
microthread sample at room temperature.  A Vortex Genie was used to lightly mix the lysis buffer 
and microthread sample.  The sutures was removed and stained with Hoechst (0.5 µL in 3000 µL of 
PBS for 5 minutes) to confirm all cells have been removed.  Using a micropipette, 100 µL were 
added to four wells of a 96 well plate, these four samples were averaged to calculate the averge 
number of cells per cm of suture. This was repeated for all samples.  The 96 well plate was placed in 
a Victor3 1420 Plate Reader to record the optical density at 480 nm.  A standard curve was created 
using the optical densities and the know cell numbers in rows 1 through 4.   
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Chapter 4: Results 
4.1 Aim 1 
4.1.1 Preliminary Fibrin Degradation 
Six seeded sutures were plated in a twelve well plate, three with Aprotinin and three with 
MSCGM.  Media changes occurred every three days and plate was lightly swirled to move suture in 
plate and keep the sutures free floating.  MSCGM sutures were degraded at Days 10, 13, and 15.  
Aprotinin sutured remained intact at these time points.  This experiment was used to determine the 
ending time-point for the Fibrin Degradation ELISA.  Day 9 was used so MSCGM sutures would not 
be completely degraded.   
4.1.2 Fibrin Degradation ELISA 
An FDP ELISA kit was used to determine the concentrations of FDP found in media after 
sutures had been cultured for 3, 6, and 9 days. A distinct decrease in FDP production was observed 
to correlate with an increase in the aprotinin concentration of the media.  A two-way ANOVA was 
used to determine significant differences between groups (p<0.05).  All FDP concentrations and 
standard deviations (µg/mL) are displayed in   
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Table 3.  At Day 3, Aprotinin-0 had significantly higher concentrations of FDP when compared 
to all other groups (Aprotinin-50, Aprotinin-10, Aprotinin-5, Aprotinin-1, and Aprotinin-0; n = 6 
within each group, p<0.05).  Likewise at Day 3, Aprotinin-100 had significantly less FDP when 
compared to FDP concentrations observed in all other groups (Aprotinin-50, Aprotinin-10, 
Aprotinin-5, Aprotinin-1, and Aprotinin-0; n = 6 within each group, p<0.05).  At Day 6, Aprotinin-100 
had significantly less FDP than Aprotinin-50, Aprotinin-5, Aprotinin-1, and Aprotinin-0 (n = 6 for all 
groups, p<0.05).  At Day 9, a significant decrease in FDP concentrations was observed between 
Aprotinin-100 and Aprotinin-50, Aprotinin-10, Aprotinin-1, and Aprotinin-0, with n = 6 in all groups 
(p<0.05).  The comparison of FDP concentrations at each Day are depicted in Figure 7 and all groups 
and time points are shown in Figure 8.   
Every three days media was collected and analyzed for FDP concentrations; however this 
only measures the amount of degradation that occurred during the previous days.  Figure 9 (and   
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Table 3) depicts the cumulative masses of FDP over the nine days.  Data separated by day is 
displayed in Figure 10.  Statistics were determined using a two-way ANOVA, and significance was 
determined at p = 0.05.  At Day 3, Aprotinin 0 had significantly more FDP mass when compared to 
Aprotinin-5, Aprotinin-10, Aprotinin-50, and Aprotinin-100 (n=6, p>0.05).  At this same time point, 
Aprotinin-100 exhibited significantly less FDP mass when compared to all other groups (Aprotinin-0, 
Aprotinin-1, Aprotinin-5, Aprotinin-10, and Aprotinin-50).  At Day 6, Aprotinin 0 had significantly 
more FDP mass when compared to Aprotinin-10, Aprotinin-50, and Aprotinin-100 (n=6, p>0.05).  
Aprotinin-100 exhibited significantly less FDP mass when compared to all other groups (Aprotinin-0, 
Aprotinin-1, Aprotinin-5, Aprotinin-10, and Aprotinin-50) at Day 6.  Lastly, at Day 9 Aprotinin 0 had 
significantly more FDP mass when compared to Aprotinin-5, Aprotinin-10, Aprotinin-50, and 
Aprotinin-100 (n=6, p>0.05).  At this same time point, Aprotinin-100 exhibited significantly less FDP 
mass when compared to all other groups (Aprotinin-0, Aprotinin-1, Aprotinin-5, Aprotinin-10, and 
Aprotinin-50).   
Results from this experiment indicated that Aprotinin-100 had the least degradation.  For all 
of the following experiments, only Aprotinin-100 was used.  “Aprotinin” will now refer to Aprotinin-
100, or 100 µg of Aprotinin per 1 ml of MSCGM.  Likewise, Aprotinin-0 (0 µg of Aprotinin per 1 ml of 
MSCGM) will be referred to as MSCGM. 
  
39 
 
Table 3: Fibrin Degradation Product Concentrations (µg/mL) and Cumulative Mass (µg) at Days 3, 6, and 9 
Time-point 
Group 
(n=6, all groups) 
FDP Concentration 
 ± St Dev (µg/mL) 
FDP Cumulative 
Mass ± St Dev (µg) 
Day 3 
Aprotinin-100 8.680 ± 1.062 8.680 ± 1.062 
Aprotinin-50 11.162 ± 1.103 11.162 ± 1.103 
Aprotinin-10 11.333 ± 1.785 11.333 ± 1.785 
Aprotinin-5 11.640 ± 0.964 11.640 ± 0.964 
Aprotinin-1 12.602 ± 0.780 12.602 ± 0.780 
Aprotinin-0 14.127 ± 1.577 14.127 ± 1.577 
Day 6 
Aprotinin-100 8.967 ± 0.734 17.647 ± 1.796 
Aprotinin-50 11.003 ± 0.711 22.165 ± 1.814 
Aprotinin-10 10.947 ± 1.656 22.280 ± 3.441 
Aprotinin-5 11.167 ± 0.565 23.587 ± 1.529 
Aprotinin-1 12.361 ± 0.583 24.963 ± 1.363 
Aprotinin-0 12.898 ± 1.836 27.025 ± 3.413 
Day 9 
Aprotinin-100 9.050 ± 0.534 26.697 ± 2.330 
Aprotinin-50 11.056 ± 1.315 33.221 ± 3.129 
Aprotinin-10 11.260 ± 1.806 33.54 ± 5.247 
Aprotinin-5 10.140 ± 0.929 33.727 ± 2.458 
Aprotinin-1 12.692 ± 1.221 37.655 ± 2.584 
Aprotinin-0 12.989 ± 1.356 40.014 ± 4.769 
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Figure 7: Fibrin Degradation Product Concentration (FDP) Data and Day Data.  FDP data is reported in µg/mL.  
Bars of graph represent the average, and error bars represent standard deviations.  Sample size was 6 sutures 
for each experimental group.  * represents 0.05 significance as determined by an ANOVA. 
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Figure 8: Fibrin Degradation Product (FDP) Data.  Sutures were seeded at 100,000 cells for 24 hours and cultured 
for 9 days with media collections at Days 3, 6, and 9.  Concentrations of FDP were used to quantify degrataion.  
Sample size of 6 sutures were used for each experimental group.  * represents 0.05 significance as determined 
by a two way ANOVA. 
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Figure 9: Cumulative FDP Mass.  FDP masses were determined at each time-point and each bar displays the FDP 
mass at each day and the cumulative masses.  The error bars depict the cumulative standard deviation at each 
time-point. 
 
43 
 
 
Figure 10: Cumulative FDP Mass at Days 3, 6, and 9.  Bars represent average FDP mass in µg and error bars 
represent standard deviations.  *represents a 0.05 significance level between Aprotinin-100 and + represents a 
0.05 significance level between Aprotinin-0 (at each day). 
 Lastly, when examining the response of cumulative FDP production (in terms of cumulative 
mass) in response to aprotinin concentration.  This data is displayed in Figure 11.  Curves were fit using a 
logarithmic decay function.  It appears that the around the 100 µg/ml aprotinin concentration that FDP 
production is nearing a limit. 
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Figure 11: FDP mass production as a function of Aprotinin concentration.  Data was fit using a logarithmic decay function and 
the fit curves are displayed on the graphs 
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4.1.3 Suture Mechanics 
Thread diameters 
Diameters of sutures were recorded at Day 3, prior to mechanical testing.  Sutures were 
placed on a glass slide and images were acquired using a Leica DM LB2 microscope at 5 x.  The 
diameters of sutures ± standard deviations (in mm) are displayed in Figure 12.  The sample size for 
suture diameters are as follows Aprotinin (n=6), MSCGM (n=6), Aprotinin no cells (n=3), MCGM no 
cells (n=3), and PBS no cells (n=4).  The average diameter and standard deviation of each group is 
depicted in  
Table 4.  An ANOVA was used to determine the significance between groups. Significant 
differences (p<0.05) were observed: between MSCGM and MSCGM-unseeded/Aprotinin/MSCGM 
unseeded/PBS unseeded and between Aprotinin and Aprotinin-unseeded/MSCGM/MSCGM 
unseeded (also depicted in Figure 12). 
 
Figure 12: Suture diameters of seeded and unseeded sutures.  Sutures were plated (followed standard seeding) 
for 3 days.  Diameters were recorded by placing the suture on a glass slide and imaging on a LEICA DM LB2 
microscope and recording 6 diameters across the length of the suture and taking the average.  1 represents a 
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0.05 significance between seeded Aprotinin, 2 represents a 0.05 significance between non-seeded Aprotinin, 3 
represents a 0.05 significance between seeded MSCGM, and 4 represents a 0.05 significance between non-
seeded MSCGM.  Significance was determined using a one way ANOVA. 
 
Table 4: Suture Diameters after 3 days in culture (mm) 
 Diameter Standard Deviation 
Aprotinin 1.288 0.106 
MSCGM 1.003 0.088 
Aprotinin-unseeded 1.496 0.065 
MSCGM-unseeded 1.702 0.050 
PBS-unseeded 1.289 0.092 
 
 
Mechanical Data 
 Sutures were seeded with a 100,000 hMSC suspension for 24 hours.  Following seeding, 
sutures were plated in either MSCGM or MSCGM supplemented with aprotinin for 3 days.  
Following suture diameter measurement, sutures were mechanically loaded to failure on an 
Instron.  Force-displacement data was converted to stress-strain data (shown in Figure 13).  The UTS 
was determined by the stress at which the suture failed, likewise this point was also the SAF.  E was 
calculated by the linear region between the UTS and 0,0 starting point.  If the curve was not linear 
to 0,0, the E was calculate in the linear portion of the curve. 
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Figure 13: Stress-Strain Curve.  After diameters were recorded, sutures were loaded into the Instron and 
mechanically loaded to failure.  A Stress-Strain curve was calculated from the force-displacement data recorded 
by the Instron.  The highest stress is the UTS, the strain value of the UTS is the SAF, and the slope of the linear 
region between the UTS and the starting 0,0 point is the E.   
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 Figure 14 depicts the UTS data for seeded sutures.  Seeded sutures exposed to aprotinin 
failed at a significnatly higher UTS when compared to sutures cultured in MSCGM alone (n = 6, p < 
0.05, one-way ANOVA).  Unseeded controls were also tested, this data is displayed in Figure 15.  
Unseeded sutures cultured in Aprotinin also exhibited a significantly higher UTS when compared to 
sutures cultured in MSCGM alone (n = 3, p < 0.05, one-way ANOVA).  A significanct difference was 
observed between the Aprotinin and MSCGM seeded and their unseeded counterparts (p < 0.05, 
one way ANOVA).  This and other sifnificant observations are shown in Figure 15.   UTS values are 
shown in Table 5.   
 
Figure 14: Ultimate Tensile Strength Data for seeded sutures.  Sutures were seeded as previously described.  
Seeded sutures cultured in aprotinin supplemented media had a significant increase in UTS when compared to 
those cultured in MSCGM alone.  * represents 0.05 significance level as determined by a one way ANOVA. 
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Figure 15: Ultimate Tensile Strength Data for seeded and unseeded sutures.  Sutures were seeded as previously 
described, while unseeded sutures underwent the same conditions, with no cells.  Unseeded sutures had 
significantly higher UTS when compared to their seeded counterparts.  1 represents a 0.05 significant difference 
between seeded aprotinin sutures, 2 represents a 0.05 significant difference between non-seeded aprotinin 
sutures, 3 represents a 0.05 significant difference between seeded MSCGM sutures, 4 represents a 0.05 
significant difference between non-seeded MSCGM sutures.  Significance was determined using a one-way 
ANOVA. 
  
Table 5: Ultimate Tensile Strength values for seeded and unseeded sutures 
Group UTS (MPa) Standard Deviation (MPa) 
Aprotinin – hMSCs 0.070 0.036 
MSCGM – hMSCs 0.027 0.021 
Aprotinin – Unseeded 0.975 0.239 
MSCGM – Unseeded 0.495 0.155 
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A similar trend was also observed between the E values of seeded sutures.  E data is shown 
in Table 6 had significantly higher than those observed in the MSCGM alone group; this is displayed 
in Figure 16: hMSC seeded suture modulus (E) Data.  Sutures were seeded as previously described.  Seeded 
sutures cultured in aprotinin supplemented media had a significant increase in modulus when compared to those 
cultured in MSCGM alone.  * represents 0.05 significance level as determined by a one way ANOVA. (p < 0.05, 
one-way ANOVA).  When examining the E values of seeded (n = 6) and unseeded (n = 3) sutures, the 
unseeded counterparts had a much higher E however, only Aprotinin exhibited a significant 
difference, shown in Figure 17: Suture Modulus (E) Data, seeded and unseeded controls.  Sutures were seeded 
in a manner previously described and mechanically loaded to failure.  Seeded sutures in both the   1 represents a 
0.05 significant difference between seeded aprotinin sutures, 2 represents a 0.05 significant difference between 
non-seeded aprotinin sutures, 3 represents a 0.05 significant difference between seeded MSCGM sutures, 4 
represents a 0.05 significant difference between non-seeded MSCGM sutures.  Significance was determined using 
a two way ANOVA. (p < 0.05, one-way ANOVA).  
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Figure 16: hMSC seeded suture modulus (E) Data.  Sutures were seeded as previously described.  Seeded sutures 
cultured in aprotinin supplemented media had a significant increase in modulus when compared to those 
cultured in MSCGM alone.  * represents 0.05 significance level as determined by a one way ANOVA. 
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Figure 17: Suture Modulus (E) Data, seeded and unseeded controls.  Sutures were seeded in a manner previously 
described and mechanically loaded to failure.  Seeded sutures in both the   1 represents a 0.05 significant 
difference between seeded aprotinin sutures, 2 represents a 0.05 significant difference between non-seeded 
aprotinin sutures, 3 represents a 0.05 significant difference between seeded MSCGM sutures, 4 represents a 
0.05 significant difference between non-seeded MSCGM sutures.  Significance was determined using a two way 
ANOVA. 
 
Table 6: Modulus values for seeded and unseeded sutures. 
Group E (MPa) Standard Deviation (MPa) 
Aprotinin – hMSCs 0.063 0.029 
MSCGM – hMSCs 0.021 0.014 
Aprotinin – Unseeded 0.937 0.237 
MSCGM – Unseeded 0.495 0.227 
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Figure 18: Suture Strain at Failure (SAF).  Sutures were seeded in a manner previously described and 
mechanically loaded to failure.  Seeded sutures saw a slight decrease in SAF when compared to their unseeded 
counterparts.  1 represents a 0.05 significant difference between seeded aprotinin sutures, 3 represents a 0.05 
significant difference between seeded MSCGM sutures.  Significance was determined using a two-way ANOVA. 
 
Table 7: Strain at Failure values for seeded and unseeded sutures 
Group SAF (Strain) Standard Deviation (Strain) 
Aprotinin – hMSCs 1.164 0.354 
MSCGM – hMSCs 1.158 0.493 
Aprotinin – Unseeded 1.702 0.183 
MSCGM – Unseeded 2.079 0.358 
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4.2 Aim 2 
4.2.1 Cell Viability 
LIVE/DEAD stained images are shown in Figure 19.  5,600 hMSCs were seeded on each 
coverslip.  The number of cells was quantified using ImageJ.  Results from the LIVE/DEAD were 
recorded in percent live cells and are shown in Figure 20 box plot (data in Table 8) and Figure 20 bar 
chart.  Cells cultured in media supplemented with Aprotinin had 97.08 ± 2.00% live cells, compared 
to the control media’s 97.84 ± 1.33%.  A student’s T-test was used to test significance between 
MSCGM and Aprotinin groups (n = 6 within each group).  No significant difference in the percent of 
live cells was observed between groups at the 0.05 significance level (with a statistical power of 
0.29) 
 
 
Figure 19: LIVE/DEAD stained hMCS on coverslips.  The first image depicts hMSCs cultured in MSCGM 
0+aprotinin, the second image depicts cells cultured in standard MSCGM.  The third image depicts dead controls; 
cells were cultured in MSCGM and killed using 70% ethanol. Nuclei are stained with Hoechst and fluoresce blue, 
calcein fluoresces green indicating live cells, and ethidium stains dead cells red.   
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Figure 20: LIVE/DEAD analysis.  A is a boxplot shows the depicting the spread of the live percentages, B depicts 
the average percentage of live cells (Aprotinin: 97.78 ±1.43%, SCGM 97.87±1.25%).  hMSCs were cultured in 
either MSCGM or MSCGM -100.  There was no significant difference between the two data sets at the 0.05 
significance level. 
Table 8: LIVE/DEAD boxplot data 
Live cells (%) Aprotinin MSCGM 
Minimum 94.16 95.50 
Quartile 1 95.47 97.00 
Median 97.29 98.06 
Quartile 3 98.73 98.90 
Maximum 99.30 99.07 
 
4.2.2 Cell Proliferation 
Proliferation was assessed using a stain for the proliferation marker Ki-67, Figure 21. 5,600 
hMSCs were seeded on each coverslip.   Like the LIVE/DEAD analysis, hMSCs were counted using 
ImageJ.  hMSC nuclei fluoresce blue and Ki-67 fluoresce red, making Ki-67 positive cells appear a 
red/purple color.  Figure 22 show the spread percentages of Ki-67+Error! Reference source not 
found. hMSCs.  Figure 22 displays the average percentage of Ki-67 positive cells between hMSCs 
cultured in either MSCGM (19.16 ± 14.78%) or Aprotinin (19.65 ± 5.86%), Table 9: Percent Ki-67 
positive hMSCs on glass coverslips displays additional statistical information.  A student’s t-test was 
used to compare the two data sets; and at the 0.05 significance level, no differences were observed 
(with a statistical power of 0.03). 
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Figure 21: Ki-67 stain on hMSCs.  hMSCs were cultured in aprotinin supplemented MSCGM or MSCGM alone.  
hMSCs were stained with Hoechst and anti-Ki-67.  Nuclei are stained blue (first column0.  Ki-67, a proliferation 
marker is stained red (second column).  White arrows indicate Ki-67+hMSCs.  A composite of the two images is 
shown in the third column. 
 
Figure 22: Ki-67 analysis.  A is a boxplot shows the depicting the spread of percentages of Ki-67 + cells, B depicts 
the average percentage of Ki-67+ cells.  hMSCs were cultured in either MSCGM or Aprotinin  There was no 
significant difference between the Aprotinin (17.54 ± 6.32%) and MSCGM (16.73 ± 13.27%) at the 0.05 
significance level. 
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Table 9: Percent Ki-67 positive hMSCs on glass coverslips 
Ki-67+ hMSCs (%) Aprotinin MSCGM 
Minimum 12.93 6.12 
Quartile 1 13.21 7.83 
Median 20.38 12.69 
Quartile 3 24.90 35.87 
Maximum 26.57 40.83 
 
4.2.3 hMSC Differentiation 
After confluence was reached in either Aprotinin or MSCGM, hMSCs underwent 
differentiation.  hMSCs were exposed to three different medias to induce adipogenic, osteogenic, 
and chondrogenic differentiations.  hMSCs were differentiated in three separate experiments; 
within each experiment, osteocytes and adipocytes with n = 3 and n = 1 for chondrocytes.  Within 
each experimental group, cells were stained to for visualization of differentiation; adipocytes with 
Oil Red O, osteocytes with Alizarin Red S, and chondrocytes with Masson’s Trichrome and Picro-
sirius.  Images were acquired of each cell type, confirming that differentiation occurred after hMSCs 
were cultured in Aprotinin and MSCGM.   
Adipogenic Differentiation 
 The presence of lipid vacuoles is a positive confirmation of adipogenic differentiation.  
Images of differentiated hMSCs stained with Oil Red S are shown in Figure 23.  These cells were 
imaged after 14 of culture, undergoing adipogenic differentiation.  Adipogenic differentiation 
consisted of alternating (every 3 days) Induction and Maintenance media for adipocyte.  After an 
additional week of differentiation, cells were stained with Oil Red O which stains lipid vacuoles red, 
as shown in Figure 24.   
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Figure 23: Adipogenic Differentiation.  hMSC differentiation into adipocytes at week 2.  hMSCs were cultured in 
media (MSCGM or Aprotinin) until 100 % confluent then differentiated.  Both groups exhibit lipid vacuole 
formation, a sign of adipocyte differentiation 
 
Figure 24: Oil Red O stained adipogenic differentiated hMSCs.  Lipid vacuoles are stained red and nuclei are 
stained blue.   
The control group, hMSCs grown to confluence then cultured for three weeks in either 
MSCGM or Aprotinin, was also stained with Oil Red to determine if any adipogenic differentiation 
occurred.  Lipid vacuoles within adipocytes are stained red, while non-differentiated cells retain 
none of the red stain as see in Figure 25.   
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Figure 25: Oil Red Stain of hMSCs.  hMSCs were cultured (in Aprotinin or MSCGM) for 3 weeks.  Lipid vacuoles 
are stained red and nuclei are stained blue, however no lipid vacuoles were observed. 
Osteogenic Differentiation 
 hMSCs were cultured in either Aprotinin or MSCGM until confluence was reached; then 
osteogenic differentiation media was fed to cells.  During osteogenic differentiation hMSC exhibit a 
more cuboidal morphology, as shown in Figure 26.   
 
Figure 26: hMSC osteogenic differentiation – week 2, hMSCs begun to exhibit more cuboidal shape in both the 
aprotinin and MSCGM groups. 
 hMSCs were exposed to aprotinin or MSCGM then differentiated for 21 day in osteogenic 
induction media.  Following differentiation, wells were stained with alizarin red, which stains for 
calcium deposits.  Figure 27 shows images stained calcium deposits of differentiated hMSCs.    
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Figure 27: Alizarin Red S Stain – Stains calcium deposits red.  hMSCs were cultured in either aprotinin or 
standard MSCGM until confluence, then differentiated for 21 days.   
 In addition to the hMSC differentiated osteocytes, hMSCs were cultured for 3 weeks at 
confluence in either MSCGM or Aprotinin.  These hMSCs were also stained with Alizarin Red to 
determine if there was any calcium production.  The undifferentiated hMSCs stained with alizarin red 
are shown in Figure 28.   
 
Figure 28: hMSCs stained with Alizarin Red.  No calcium deposit formation, shown by no red stain detection, or 
the cuboidal cell morphology, indicating no osteogenic differentiation 
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Chondrogenic Differentiation 
 hMSCs were grown using aprotinin or MSCGM.  Once 250,000 hMSCs were grown; cells 
were pelleted and fed chondrogenic media supplemented with TGF-β.  After twenty-one days of 
differentiation, pellets were fixed, paraffin embedded, and sectioned.  Chondrocyte sections were 
stained for collagen using Masson’s Trichrome shown in Figure 29.  Collagen is stained blue, nuclei 
are stained black and cytoplasm and keratin are both stained red. 
 
Figure 29: Chondrocyte Pellets stained with Masson's Trichrome.  Collagen is stained blue, neucli are black, and 
cytoplasm and keratin are red.  Both the aprotinin and MSCGM pellets expressed collagen formation. 
 A picro-sirius collagen stain was also performed to detect collagen.  Picro-sirius is more 
efficient at collagen detection than Masson’s Trichrome [78, 79].  Figure 30 shows a picro-sirius 
stain of the hMSC differentiated chondrocyte pellets.   
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Figure 30: Picro-sirius Stain of Chondrocyte Pellets.  Collagen is stained red, while nuclei are stained black.  
hMSCs exposed to either Aprotinin and MSCGM differentiated into collagen producing chondrocytes.   
 
4.3 Aim 3 
4.3.1 hMSC Quantities on Fibrin Sutures 
 The CyQuant Assay uses a DNA stain and correlates the optical density of stained DNA to 
the quantity of cells.  Sutures were seeded for twenty four hours and plated with Aprotinin or 
MSCGM, for 0, 1, 2, 3, and 5 days.  Each experimental group had a sample size of six.  A two-way 
ANOVA was used to determine significance between groups.  All data, including optical densities, 
cell quantities, standard curves, and ANOVA tables are listed in Appendix H: Cell  
All cell quantity data is reported as average ± SEM and displayed in Table 10.  At Day 0, 
sutures seeded in Aprotinin had 11,399 ± 1,133 cells, while MSCGM had 13,838 ± 2,764 cells.  
Aprotinin supplemented sutures had 14,696 ± 2,560 hMSCs compared to the 12,810 ± 1,153 found 
on MSCGM sutures at Day 1.  When comparing sutures at Day 2, Aprotinin sutures (24,355 ± 3,516) 
had significantly more hMSCs attached to the suture surface when compared to MSCGM sutures 
(12,435 ± 1,495).  Sutures cultured in aprotinin for three days were shown to have 28,508 ± 4,570 
hMSCs, significantly more than those adhered to the surface MSCGM sutures, 13,949 ± 3,030.  At 
Day 5 sutures cultured in the Aprotinin supplemented media showed a significant increase in the 
number of hMSCs on the sutures surface (31,648 ± 3,899 and 20,643 ± 4,314, respectively).  Figure 
31 depicts the quantity of hMSCs attached to fibrin suture surface. 
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Figure 31: CyQuant Data.  Number of cells adhered to fibrin sutures at Days 0, 1, 2, 3, and 5 when cultured in 
MSCGM or Aprotinin.  On Days 2, 3, and 5 sutures cultured in Aprotinin has significantly more hMSCs on the 
sutures surface when compared to MSCGM alone.  * represents a significant difference between groups, as 
determined by an ANOVA.   
Table 10: Cell quantities adhered to the fibrin suture surface 
Time-Point Group Number of hMSCs SEM (# of cells) 
Day 0 
Aprotinin 11,399 1,133 
MSCGM 13,838 2,764 
Day 1 
Aprotinin 14,696 2,560 
MSCGM 12,810 1,153 
Day 2 
Aprotinin 24,355 3,516 
MSCGM 12,435 1,495 
Day 3 
Aprotinin 28,508 4,570 
MSCGM 13,949 3,030 
Day 5 
Aprotinin 31,648 3,899 
MSCGM 20,643 4,314 
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When examining the sutures cultured in aprotinin-supplemented MSCGM, Days 2 (24,355 ± 
3,516), 3 (28,508 ± 4,570), and 5 (31,648 ± 3,899) each showed a significant increase in the number 
of cells adhered to the suture’s surface when compared to both Day 0 (11,399 ± 1,133) and Day 1 
(14,696 ± 2,560).  Figure 32 depicts the number of hMSCs on the suture surface of sutures cultured 
in Aprotinin.   
 
Figure 32: Cell Quantities adhered to sutures (Aprotinin only).  An increase in the number of cells on the suture’s 
surface was observed.  * represents a 0.05 significance level difference between Day 0, + * represents a 0.05 
significance level difference between Day 1. 
 Looking at the number of cells attached to the sutures, a large jump (approximately 10,000) 
occurred between days 1 and 2, almost double the number of cells.  Knowing the passage doubling time 
of hMSCs is around 5 to 7 days, an increase of almost double warrants further experimentation.  To 
investigate this increase in hMSCs, sutures were seeded and plated for 0, 1, or 2 Days, with an n = 3 in 
each group, and stained of Ki-67.  This experiment determined the percentage of proliferating cells on 
sutures. The number of proliferating cells is depicted in Table 11Table 11.  At Day 2, sutures cultured in 
aprotinin showed a significant increase in ki-67 positive cells, when compared to sutures cultured in 
aprotinin at Days, 0 and 1.  This same trend was also observed in sutured cultured in MSCGM alone, with 
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a significant increase between Day 2 and both Days 0 and 1.   Additionally at Day 2, sutures cultured in 
aprotinin had a significant increase in the number of Ki-67 positive cells when compared to MSCGM 
alone sutures.  Significance was determined using a two way ANOVA, at 0.05 significance level.   
Table 11: Percent of Ki-67 positive hMSCs on fibrin sutures. 
Time-point Group 
Proliferating hMSCs 
 (% Ki-67 +) 
Standard Deviation 
 (% Ki-67 +) 
Day 0 
Aprotinin 7.37   2.97 
MSCGM 4.82   0.98 
Day 1 
Aprotinin 9.58   1.36 
MSCGM 6.18   1.33 
Day 2 
Aprotinin 42.05   11.44 
MSCGM 29.24   2.46 
  
 
Figure 33: Ki-67 on Sutures (Days 0, 1, 2).  At Day 2, Aprotinin sutures showed significant increase in proliferating 
cells when compared to MSCGM alone sutures.  Both groups at Day 2 (Aprotinin and MSCGM), had a significant 
increase in proliferating cells when compared to both Days 0 and 1 (when compared within each media group).  
* represents a 0.05 significance level between Day 2 MSCGM and + represents a 0.05 significance level between 
Day 2 Aprotinin. 
66 
 
Chapter 5: Discussion 
 This project determined the effects of aprotinin on sutures by quantifying degradation by FDP 
concentrations in media and determining suture mechanics.  Aprotinin supplementation did not seem to 
affect hMSC viability, determined by LIVE/DEAD, hMSC proliferation, quantified by Ki-67 stain, and 
hMSC differentiation capacity, by differentiating hMSCs into adipocytes, osteocytes, and chondrocytes 
and staining to confirm differentiation.  Lastly, the number of hMSCs that were adhered to fibrin sutures 
was determined. 
5.1 Alternatives to Aprotinin 
 In addition to aprotinin, there are two primary antifibrinolytic drugs that could be 
considered instead of aprotinin to use to control fibrinolysis.   These two drugs are Tranexamic acid 
(TA) and Ɛ-aminocaproic acid (AA) and similar to aprotinin have been used in cardiac surgery to 
reduce bleeding [80].  If TA and AA were added to MSCGM, like aprotinin in this study, these acids 
may alter the pH of the MSCGM and growth factors found in the media.  The addition of aprotinin 
did not appear to affect the pH of MSCGM in this study.   
 When compared to aprotinin, TA controls in vivo degradation extremely similar, if not better 
than aprotinin [80-82].  When investigated in an in vitro environment however, TA was shown to be 
less effective at control fibrin degradation when compared to aprotinin. Fibrin degradation was 
quantified in terms of thrombus mass, which thrombi formed when aprotinin was used had a 
significantly lower mass when compared to TA [81].  Both aprotinin and TA appear to have 
differences in terms of the method and potential to inhibit coagulation; in vitro, aprotinin is an 
effective inhibitor of the intrinsic (contact) coagulation pathway, while TA acid does not inhibit this 
coagulation pathway [81]. 
 Similar to TA, AA showed similar reductions on fibrinolysis in vivo when compared to 
aprotinin [80].  In addition to investigating the effect on fibrinolysis, the plasma levels of 
proinflammatories and anti-inflammatories have also been investigated [83].  When compared to 
aprotinin, AA showed increased levels of plasma proinflammatory [interleukin-6 (IL-6)] and anti-
inflammatory [interleukin-10 (IL-10)] cytokines [83].  While it has yet to be determined if this 
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increase in IL-6 and IL-10 has any effect on clinical outcome, it seems to indicate that aprotinin has 
less of an immune response when compared to AA.    
5.2 Maximum Aprotinin Dosages 
 We observed a decrease in fibrin degradation, with an increase in aprotinin concentrations 
up to 100 µg/ml of aprotinin.  There were several factors influence the 100 µg/ml cap.  When 
looking at aprotinin concentrations in clinical settings aprotinin concentrations are measure in units 
of Kallikrein Inhibitor Units (KIU) per mL.  One milligram of aprotinin is equivalent to 7,143 KIU [84, 
85].  The 100 µg/ml of aprotinin concentration equates to approximately 700 KIU/ml.  In a study, a 
full dose of aprotinin constitutes of: an initial 2 injections of 2,000,000 KIU, a constant infusion 
500,000 KIU/hr, followed by a cardio-pulmonary bypass prime of 2 injections of 2,000,000 KIU.  
Following a full dose administration, patients showed aprotinin levels of 401 ± 91 KIU/ml, with a 
patient high of approximately 550 KIU/ml [86].  Other studies have also investigated the effect of 
aprotinin on fibrin scaffold degradation.  These studies had aprotinin concentrations between 0 and 
50 µg/ml [87-89].  Lastly, inhibition of plasmin and kallikrein have been shown in vitro to be 125 
KIU/ml and 500 KIU/ml, respectively [90], much higher than the reported 50 KIU/ml for plasmin and 
200 KIU/ml for kallikrein reported in patients [91].  Our concentration of 100 µg/ml of aprotinin (or 
approximately 700 KIU/ml) was slightly higher than the highest levels observed in patients, high 
enough to inhibit both plasmin and kallikrein, and was comparable to other in vitro studies.       
5.3 Fibrin Degradation 
When using the FDP ELISA to determine the concentrations of FDP, non-seeded controls 
were used to establish baseline degradations.  Aprotinin, MSCGM, and PBS were used as media for 
culture in these controls.  Sutures that were exposed to PBS seemed to degrade differently than 
other sutures.  It appeared that fibrin degraded as a mix of bulk and surface degradation, when 
seeded with hMSCs in either aprotinin or MSCGM.  Sutures became more transparent as time went 
on, which would seem to indicate bulk degradation.  However the diameter also decreased, this 
may indicate the hMSCs were eating away at the surface of the suture, and therefore surface 
degradation.  With unseeded PBS sutures neither of these two things occurred.  It appeared as if 
the sutures were minced up using scissors, in addition, the fragments of suture that were remaining 
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did not appear transparent like the other sutures.  This seems to indicate another method of fibrin 
degradation as opposed to the enzymatic degradation that occurred.  This has been reported in 
literature; that fibrin gels placed in PBS have rapidly degraded, quantified by a loss of scaffold mass 
[92].  One possible explanation for this is that being placed in a salt solution; the ionic bonds of the 
PBS were strong enough to dissociate the bonds holding the fibrin microthreads together.  Another 
possible explanation is that PBS is a very “blank” solution, meaning that there are no proteins in 
solution.   Complete medias, including MSCGM and MSCGM supplemented with aprotinin, have 
proteins in solution which may make the fibrin more stable.  
5.4 hMSC Differentiation 
In this experiment, we demonstrated that hMSCs that were exposed to aprotinin, 
differentiated into adipocytes, osteocytes, and chondrocytes.  While we did not quantify the 
amount of cells that differentiated, differentiation was observed in both the MSCGM and Aprotinin 
groups.  Our data indicated that aprotinin did not significantly affect the differentiation capacity of 
hMSCs.   
When examining the chondrogenic differentiation, Masson’s Trichrome was initially used.  
Masson’s Trichrome is a common stain used in histology to identify keratin, muscle fibers, 
connective tissue, cellular cytoplasm, and cell nuclei.  It was chosen for use in this study because it 
identifies collagen and is commonly used in histology.  Upon further literature review, one study 
compared a Masson’s Trichrome and a Picro-sirius Red stain, and found that the Picro-sirius stain 
identified collagen more consistently in detecting renal fibrosis than Masson’s Trichrome  [93].  A 
different study concluded that Picro-sirius Red was able to provide a more detailed insight on the 
structure and composition of collagen networks in cardiac tissue when compared to Masson’s 
Trichrome [78, 79].  Because of the slight amounts of collagen detected in this study using Masson’s 
Trichrome, and the ability of Picro-sirius to more easily identify collagen, a Picro-sirius stain was 
used in addition to Masson’s Trichrome to identify collagen in chondrocyte pellets.  Additionally, 
Alcian Blue may be an additional stain that could be used.  Alcian Blue stains acidic polysaccharides, 
which includes glycosaminoglycans that are found in collagen.  Alcian Blue may be a better stain to 
use for collagen detection, because rather than stain specific types of collagen (like Masson’s 
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Trichrome and Picro-sirius), Alcian blue stains the glycosaminoglycans which can be found in any 
type of collagen.   
5.5 Cellular Proliferation on Sutures 
When examining the number of hMSCs adhered to fibrin sutures, an increase was seen in 
the number of adhered cells, in both the MSCGM and Aprotinin groups (as seen in Figure 31 and 
Figure 32).   It is known that the passage doubling time of bone derived hMSCs at low passages is 
typically around 5 to 7 days [94, 95].  The passage doubling has been known to decrease depending 
on the growth factors in media [94].  In this experiment there was a large increase (approximately 
double) between days 1 and 2 of the Aprotinin, seeded sutures.  A proliferation stain was 
performed on sutures between days 0 and 2 to determine if there was any change in proliferation 
across these time points that could explain the large increase in hMSCs adhered to the sutures.  We 
did see a large increase in proliferation at Day 2 (Figure 33), which corresponds to the increase in 
adhered cells on sutures.  It may be possible that in the 3D environment of being seeded on the 
suture is somehow stimulating hMSC proliferation.  Aprotinin further stimulated proliferation of the 
hMSCs seeded on fibrin sutures for two days.  We did not investigate the mechanism in which 
aprotinin affected hMSC proliferation, but we clearly observed a large increase in proliferation, 
indicating that some form of stimulation in proliferation occurred when seeded sutures were 
cultured for two days in aprotinin.   
The seeding procedure is very manual and has a substantial learning curve.  Because of this 
there will be a degree of variability between people seeding sutures and even different batches 
seeded by the same person.  The Cyquant assay is terminal, meaning the cells and sutures are 
destroyed during the analysis.  This prevents the investigation of the number of cells adhered to a 
single suture over various time points.    
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Chapter 6: Future Work and Implications 
 The use of fibrin sutures is a novel method of delivery hMSCs to the infarcted heart used by 
the Gaudette Lab.  It has improved engraftment and localization when compared to traditional IM 
injections [53].  In addition to these benefits, it is a simple method that surgeons could use to 
delivery hMSCs to patients without any additional training.  Multiple sutures could be used to 
deliver a desired amount of cells to a particular patient depending on the size of the infarct.  
Additionally we demonstrated that the use of aprotinin can increase the number of hMSCs when 
compared to MSCGM alone, while also retaining more of the integrity of the suture.  This can be 
used to increase the number of cells delivered to the infarct zone requiring less sutures.  Currently 
our lab uses seeded sutures to deliver hMSCs to infarcts in rat hearts.  Sutures in these experiments 
are only seeded for 24 hours then delivered to the heart and no further culturing (past the initial 
twenty-four hours of seeding) is performed.  If these sutures were cultured in Aprotinin for even 
two days before delivery to rat hearts could drastically increase the number of hMSCs delivered to 
the infarcted heart.  Without using Aprotinin, further culture of sutures after seeding was not 
possible; because the hMSCs degraded the fibrin sutures.  Using Aprotinin slowed the hMSC 
degradation of fibrin and would allow for culture before implantation.  Not only does this broaden 
the range of when seeding needs to occur, further culture after seeding has the potential to deliver 
more cells.  
This experiment did not investigate the adhesion strength of hMSCs cultured in either 
aprotinin or MSCGM.  It is possible that aprotinin may affect the adhesion strength of hMSCs to 
fibrin sutures.  In addition to how well the hMSCs adhere to the suture, how the hMSCs travel after 
delivery is also a question that can be raised.  Future studies could investigate the engraftment 
rates and where delivered hMSCs are located after suture delivery.   Additionally, adhesion 
molecules including poly-lysine, fibronectin, and laminin may alter the adhesion of hMSCs on fibrin 
sutures.  It is possible that use of an adhesion molecule coupled with culturing in aprotinin-
supplemented media may further increase the number of adhered hMSCs, due to increased 
adhesion and an elongated time in culture.  More hMSCs adhered to the sutures may alter suture 
degradation.  Additional FDP ELISAs would need to be performed to assess the degradation of 
protein coated sutures. 
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Aprotinin inhibits binding of enzymatic molecules.  All of the experiments performed in this 
study were performed in vitro.  If the binding of enzymatic molecule binding sites were blocked on 
the sutures, it is possible that the suture may take more time to degrade in vivo.   In vivo studies 
could be able to determine if aprotinin supplemented fibrin sutures affect the degradation time 
following implantation.   
 hMSCs have been shown to aid in the healing process, but will not differentiate into 
contracting cardiomyocytes.  Induced pluripotent stem cells (iPSC), are cells that have had genes 
altered to become stem cells.  The initial cells are often fibroblasts.  Efforts have been made to seed 
iPSCs on fibrin sutures, and the effect of aprotinin on iPSC cells and seeding on fibrin sutures is 
currently unknown. 
 All studies done on seeded fibrin suture delivery to infarcted hearts have been performed 
on rat models.  Before this technology can be applied clinically, it must be further and extensively 
studied in both small and large animal models.  Aspects that would need investigation include an 
autologous cell isolation and expansion (to eliminate immune response to cells), mechanical 
function of the heart, engraftment rates of delivered cells,  degradation of sutures in vivo, and long 
term effects of delivery fibrin.  The type of fibrin used is another area that may require further 
investigation.  Currently, our lab uses bovine components when extruding fibrin microthreads.  
Determining tissue and immune response of interspecies protein implantation would need to be 
investigated.  Following successful safety and efficacy trials in all animal trials, isolated clinical trials 
may begin.  Success in isolated clinical trials may lead to further use.   
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Conclusion 
The goal of this project was to characterize and explore the effects of aprotinin supplementation 
on both hMSCs and hMSC seeded biological sutures.  Exposing sutures to aprotinin, exhibited low levels 
of FDP as well as higher suture mechanical strength and modulus.  Aprotinin did not appear to effect 
hMSC viability, proliferation, or differentiation.  Lastly, when cultured in Aprotinin, the number of 
hMSCs adhered to the fibrin sutures was increased compared to MSCGM alone.  When supplemented 
with 100 µg/ml of aprotinin, we observed a 33% reduction in FDP mass over nine days, a 2.6 x increase 
in suture UTS, up to a 2.0 increase in the number of hMSCs adhered to sutures, and an increase of up to 
1.4x the proliferation of hMSCs on sutures.  The use of aprotinin will allow hMSC seeded sutures to 
remain in culture for more extended periods of time (when compared to MSCGM alone) while 
increasing the number of adhered hMSCs while extending the window of use for hMSC seeded fibrin 
biological sutures. 
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Appendix A: Fibrin Degradation ELISA Results 
  Exp 1 Exp 2 AVG STDEV 
Day 3 
100 
7.622936 9.228964 
8.679547 1.062165 
9.910392 9.570009 
7.319273 8.425706 
50 
10.88719 11.90369 
11.1621 1.102712 
9.457667 12.65799 
10.66005 11.406 
10 
13.23196 11.71343 
11.33256 1.784957 
7.956207 11.73842 
11.24472 12.11063 
5 
9.951722 11.55223 
11.63983 0.96385 
12.82803 11.79074 
12.21712 11.49912 
1 
13.65471 11.88366 
12.60172 0.780287 
13.30805 12.61517 
12.50133 11.64742 
0 
11.43684 15.76576 
14.12667 1.576638 
15.37414 14.77188 
13.40549 14.00589 
 
  Exp 1 Exp 2 AVG STDEV 
Day 6 
100 
8.790885 8.30922 
8.967307 0.732059 
10.21902 8.55726 
8.464757 9.462697 
50 
11.04145 11.2841 
11.00328 0.711249 
10.61389 12.2332 
10.18633 10.66074 
10 
12.55242 11.8652 
10.94665 1.656087 
7.824913 11.00254 
11.66233 10.7725 
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5 
11.3138 11.16072 
11.16743 0.565316 
10.95394 10.48661 
12.1703 10.91923 
1 
13.02423 11.78728 
12.36059 0.582975 
12.51723 12.9435 
12.27846 11.61284 
0 
10.36769 12.81272 
12.8975 1.835592 
14.66589 14.47927 
11.02304 14.03639 
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  Exp 1 Exp 2 AVG STDEV 
Day 9 
100 
8.434686 8.965305 
9.050344 0.533658 
9.601762 9.756725 
8.572459 8.971127 
50 
10.49048 11.99466 
11.05617 1.314928 
9.474227 11.71798 
9.854351 12.80531 
10 
13.65471 9.984784 
11.25988 1.805767 
8.563633 11.04292 
12.06238 12.25087 
5 
11.43684 10.14689 
10.1396 0.929126 
8.596397 10.02761 
10.01662 10.61324 
1 
13.67827 12.13779 
12.69296 1.22134 
11.93878 11.44764 
14.66681 12.28848 
0 
13.90932 12.21685 
12.98867 1.355564 
13.34402 14.7018 
10.82523 12.93479 
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Appendix B: Fibrin Degradation ELISA ANOVA 
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Appendix C: Fibrin Degradation Product Mass ANOVA: 
Day3: 
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Day 6: 
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Day 9: 
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Appendix D: Suture Diameter 
Quantified using 3 images, a left (near the needle), center (approximately 2 cm from needle), and right 
(near the end of the suture) 
Aprotinin (100 micrograms of aprotinin/ml media) - hMSC seeded: 
Suture Left Max Left Min 
Center 
Max 
Center 
Min 
Right Max Right Min Average 
Aprotinin-1 1.452 0.945 1.276 1.187 1.557 1.416 1.306 
Aprotinin-2 1.025 1.290 1.328 0.900 1.748 1.487 1.253 
Aprotinin-3 1.367 1.169 1.336 1.203 1.288 0.968 1.222 
Aprotinin-4 1.406 0.988 1.448 1.307 1.589 1.200 1.323 
Aprotinin-5 1.557 1.087 1.662 1.249 1.723 1.534 1.469 
Aprotinin-6 1.603 1.373 1.215 0.929 1.077 0.768 1.161 
Average 
Diameter 
1.289 Stdev 0.106     
  
MSCGM (media alone) - hMSC seeded: 
Suture Left Max Left Min 
Center 
Max 
Center 
Min 
Right Max Right Min Average 
Control-4 1.190 0.947 1.166 0.957 1.250 1.036 1.091 
Control-5 1.290 0.788 1.277 0.575 1.577 1.307 1.135 
Control-7 1.025 0.935 0.689 0.613 1.391 0.898 0.925 
Control-10 1.063 0.680 1.261 0.831 1.093 0.828 0.959 
Control-12 1.111 0.740 1.275 1.202 1.021 0.462 0.969 
Control-13 1.171 0.747 1.047 0.768 1.125 0.757 0.936 
Average 
Diameter 
1.003 Stdev 0.088     
 
93 
 
 
Non-seeded Aprotinin (100 micrograms of aprotinin/ml media): 
Suture Left Max Left Min 
Center 
Max 
Center 
Min 
Right Max Right Min Average 
NC-
Aprotinin-1 
1.570 1.253 1.754 1.503 1.817 1.314 1.535 
NC-
Aprotinin-2 
1.753 1.508 1.663 1.358 1.640 1.272 1.532 
NC-
Aprotinin-3 
1.754 1.348 1.330 1.148 1.731 1.213 1.421 
Average 
Diameter 
1.496 Stdev 0.065     
 
 
Non-seeded MSCGM (media alone): 
Suture Left Max Left Min 
Center 
Max 
Center 
Min 
Right Max Right Min Average 
NC-MSCGM-
1 
1.990 1.781 1.923 1.499 1.827 1.435 1.742 
NC-MSCGM-
2 
1.677 1.524 1.649 1.508 2.277 1.676 1.719 
NC-MSCGM-
3 
1.676 1.412 1.689 1.539 1.830 1.732 1.647 
Average 
Diameter 
1.702 Stdev 0.050     
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Diameter ANOVA: 
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Appendix E: Suture Mechanics 
UTS 
UTS Data (Pa):  
Sample 
Aprotinin -
Seeded 
MSCGM -
Seeded 
Aprotinin -
Unseeded 
MSCGM - 
Unseeded 
PBS -
Unseeded 
1 52095.9 16654.6 801732.1 472204.3 1111005.1 
2 62925.0 2942.0 874853.8 660526.9 1459941.6 
3 42561.3 8320.1 1247399.9 352514.6 809458.4 
4 62805.5 41217.3 - - 1013624.0 
5 141816.7 55208.3 - - - 
6 57040.0 37193.8 - - - 
Average 69874.1 26922.7 974661.9 495081.9 1098507.3 
Stdev 36057.6 20671.1 239010.9 155275.3 271750.7 
 
UTS Data (MPa):  
Sample 
Aprotinin -
Seeded 
MSCGM -
Seeded 
Aprotinin -
Unseeded 
MSCGM - 
Unseeded 
PBS -
Unseeded 
1 0.05210 0.01665 0.80173 0.47220 1.11101 
2 0.06293 0.00294 0.87485 0.66053 1.45994 
3 0.04256 0.00832 1.24740 0.35251 0.80946 
4 0.06281 0.04122 - - 1.01362 
5 0.14182 0.05521 - - - 
6 0.05704 0.03719 - - - 
Average 0.06987 0.02692 0.97466 0.49508 1.12680 
Stdev 0.03606 0.02067 0.23901 0.15528 0.32553 
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UTS ANOVA: 
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E 
E Data: 
E Data (Pa):  
Sample 
Aprotinin -
Seeded 
MSCGM -
Seeded 
Aprotinin -
Unseeded 
MSCGM - 
Unseeded 
PBS -
Unseeded 
1 40875.3 10080.6 801732.1 472204.3 789784.3 
2 44609.2 7244.5 874853.8 660526.9 1197654.9 
3 47975.0 8175.1 1247399.9 352514.6 492859.4 
4 44111.3 41245.8 - - 962748.3 
5 100339.7 29363.9 - - - 
6 99178.7 29988.5 - - - 
Average 62848.2 21016.4 974661.9 495081.9 860761.7 
Stdev 28682.0 14377.5 239010.9 155275.3 296809.8 
 
E Data (MPa):  
Sample 
Aprotinin -
Seeded 
MSCGM -
Seeded 
Aprotinin -
Unseeded 
MSCGM - 
Unseeded 
PBS -
Unseeded 
1 0.04088 0.01008 0.80173 0.47220 0.78978 
2 0.04461 0.00724 0.87485 0.66053 1.19765 
3 0.04798 0.00818 1.24740 0.35251 0.49286 
4 0.04411 0.04125 - - 0.96275 
5 0.10034 0.02936 - - - 
6 0.09918 0.02999 - - - 
Average 0.06285 0.02102 0.97466 0.49508 0.86076 
Stdev 0.02868 0.01438 0.23901 0.15528 0.29681 
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E ANOVA: 
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101 
 
SAF 
SAF Data: 
SAF Data (Strain):  
Sample 
Aprotinin -
Seeded 
MSCGM -
Seeded 
Aprotinin -
Unseeded 
MSCGM - 
Unseeded 
PBS -
Unseeded 
1 1.2745 1.4106 1.8637 2.2238 2.2025 
2 1.4106 0.3990 1.5040 1.6711 2.1046 
3 0.8872 1.0177 1.7376 2.3408 2.5056 
4 1.4238 0.9993 - - 1.5561 
5 1.4134 1.8801 - - - 
6 0.5751 1.2403 - - - 
Average 1.1641 1.1578 1.7018 2.0786 2.0922 
Stdev 0.3539 0.4925 0.1825 0.3577 0.3960 
 
SAF ANOVA: 
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Appendix F: Cell Viability 
6 coverslips were seeded with 35,000 cells (approximately 5,000 cells per cm) and cultured for 7 days.  
LIVE/DEAD assay was used to determine the quantities of live and dead cells 
Aprotinin (100 micrograms of aprotinin/ml media): 
 Live Cells/Green (#) Dead Cells/Red (#) Total Cells/Blue (#) 
Coverslip 1 
254 16 270 
253 5 258 
Average (%) 96.75 3.25  
Coverslip 2 
300 4 304 
245 4 249 
Average (%) 96.54 1.46  
Coverslip 3 
342 4 246 
375 7 382 
Average (%) 98.51 1.49  
Coverslip 4 
172 17 189 
253 7 260 
Average (%) 94.16 5.84  
Coverslip 5 
281 4 285 
290 0 290 
Average (%) 99.30 0.70  
Coverslip 6 
315 9 324 
332 19 351 
Average (%) 95.91 4.09  
TOTALS 
Live Cells Avg (%) Live Cells Stdev(%) Dead Cells Avg (%) Dead Cells Stdev (%) 
97.08 2.00 2.92 2.00 
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MSCGM: 
 Live Cells/Green (#) Dead Cells/Red (#) Total Cells/Blue (#) 
Coverslip 1 
106 2 108 
96 0 96 
Average (%) 99.07 0.93  
Coverslip 2 
41 1 43 
199 0 199 
Average (%) 98.84 1.16  
Coverslip 3 
104 3 107 
134 3 137 
Average (%) 95.71 4.29  
Coverslip 4 
85 5 90 
56 2 58 
Average (%) 95.50 4.50  
Coverslip 5 
64 0 64 
104 3 107 
Average (%) 98.60 1.40  
Coverslip 6 
117 3 120 
120 3 123 
Average (%) 97.53 2.47  
TOTALS 
Live Cells Avg (%) Live Cells Stdev(%) Dead Cells Avg (%) Dead Cells Stdev (%) 
97.84 1.33 2.16 1.33 
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Appendix G: Cell Proliferation 
6 coverslips were seeded with 35,000 cells (approximately 5,000 cells per cm) and cultured for 3 days.  
LIVE/DEAD assay was used to determine the quantities of live and dead cells 
Aprotinin (100 micrograms of aprotinin/ml media): 
 Total Cells - Blue (#) Ki-67+ Cells - Red (#) Ki-67+ Cells (%) 
Coverslip 1 
118 20 16.95 
157 14 8.92 
 Coverslip Average (%) 12.93 
Coverslip 2 
38 9 23.68 
64 16 25.00 
Coverslip Average (%)  
Coverslip 3 
78 16 20.51 
82 5 6.10 
Coverslip Average (%) 13.31 
Coverslip 4 
28 4 14.29 
28 8 32.00 
Coverslip Average (%) 23.14 
Coverslip 5 
101 14 13.86 
56 22 39.29 
Coverslip Average (%)  
Coverslip 6 
118 16 13.56 
83 18 21.69 
Coverslip Average (%) 17.63 
TOTALS 
Ki-67+ Avg (%) Ki-67+ Stdev (%) 
19.65 5.86 
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MSCGM: 
 Total Cells - Blue (#) Ki-67+ Cells - Red (#) Ki-67+ Cells (%) 
Coverslip 1 
220 18 8.18 
271 11 4.06 
 Coverslip Average (%) 6.12 
Coverslip 2 
206 12 5.83 
228 25 10.96 
Coverslip Average (%) 8.40 
Coverslip 3 
12 9 75.00 
60 4 6.67 
Coverslip Average (%) 40.83 
Coverslip 4 
56 4 7.14 
51 13 25.49 
Coverslip Average (%) 16.32 
Coverslip 5 
153 18 11.76 
157 10 6.37 
Coverslip Average (%) 9.07 
Coverslip 6 
22 11 50.00 
76 14 18.42 
Coverslip Average (%) 34.21 
TOTALS 
Ki-67+ Avg (%) Ki-67+ Stdev (%) 
19.16 14.78 
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Appendix H: Cell Adhesion 
Day 0 Data: 
Standard 
Curve 
   
MSCGM 
   
Aprotinin 
  
  
72917 82550 88314 92049 10580 8253 15890 8791 9731 10634 10127 12691 
42793 39538 79890 64822         10694 11745 17362 15655 
34242 24883 27770 29191 7814 12718 8675 8483 8951 9365 8887 9049 
16731 13668 15480 20372 12505 13943 12804 11275 8708 10927 10427 11991 
9680 10117 8529 7119         9243 12217 11085 9482 
6318 5505 5588 5978                 
4027 3726 3785 2596                 
2427 2326 2375 2354                 
OD 
83958 
 
Cells 
30000 
 56761 15000 
 29022 7500 
 16563 3750 
 8861 1875 
 5847 937.5 
 3534 468.75 
 2371 234.375 
 
   1 Correlation Coeff 
 
MSCGM OD 
   
Cells 
   
Cells*5 
   1 10580 8253 15890 8791 2195.316 1392.036 4028.328 1577.753 10976.58 6960.178 20141.64 7888.766 
2 7814 12718 8675 8483 1240.493 2933.354 1537.71 1471.432 6202.464 14666.77 7688.55 7357.158 
3 12505 13943 12804 11275 2859.826 3356.224 2963.041 2435.23 14299.13 16781.12 14815.2 12176.15 
             Aprotinin OD 
   
Cells 
   
Cells*5 
   1 9731 10634 10127 12691 1902.241 2213.957 2038.94 2924.033 9511.206 11069.78 10194.7 14620.17 
2 10694 11745 17362 15655 2234.669 2597.474 4536.462 3947.206 11173.34 12987.37 22682.31 19736.03 
3 8951 9365 8887 9049 1632.985 1775.898 1610.892 1666.815 8164.926 8879.49 8054.462 8334.074 
4 8708 10927 10427 11991 1549.102 2315.1 2142.5 2682.393 7745.508 11575.5 10712.5 13411.97 
5 9243 12217 11085 9482 1733.784 2760.408 2369.642 1816.286 8668.918 13802.04 11848.21 9081.432 
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Days 0, 1, & 2 Data: 
94202 91648 95667 94476 21461 20746 22364 22018 25863 23569 27972 21856 
54520 54791 54706 55387 28046 23822 31740 22109 17368 21991 20620 18011 
35085 37470 34625 36295 16961 21825 18844 21429 18641 36702 31763 30698 
26996 26288 25069 25008 24010 24689 27839 25087 18942 23873 19383 19676 
21974 20442 21029 21305 25422 25710 25218 26197 22435 26472 21123 23922 
20135 18119 19033 17341         23195 25354 23550 26173 
18858 17492 17232 18531         27503 18146 19021 20161 
15996 15988 15603 16388                 
OD 
93998 
 
Cells 
30000 
54851 15000 
35869 7500 
25840 3750 
21188 1875 
18657 937.5 
18028 468.75 
15994 0 
  
0.999951 
Correl 
Coeff 
 
 
 
OD 
   
Cells 
   
Cells*5 
   AD0 21461 20746 22364 22018 1993.723 1717.304 2342.822 2209.059 9968.613 8586.518 11714.11 11045.29 
             AD1 28046 23822 31740 22109 4539.484 2906.485 5967.584 2244.239 22697.42 14532.43 29837.92 11221.2 
 
16961 21825 18844 21429 254.0226 2134.445 981.9904 1981.351 1270.113 10672.23 4909.952 9906.757 
             
 
25422 25710 25218 26197 3525.045 3636.386 3446.179 3824.66 17625.23 18181.93 17230.89 19123.3 
AD2 24010 24689 27839 25087 2979.166 3241.667 4459.457 3395.534 14895.83 16208.34 22297.29 16977.67 
             CD0 25863 23569 27972 21856 3695.536 2808.675 4510.875 2146.43 18477.68 14043.38 22554.38 10732.15 
 
17368 21991 20620 18011 411.3688 2198.621 1668.592 659.9526 2056.844 10993.1 8342.96 3299.763 
 
18641 36702 31763 30698 903.5106 7885.893 5976.476 5564.747 4517.553 39429.47 29882.38 27823.73 
             
             
             CD1 18942 23873 19383 19676 1019.877 2926.202 1190.368 1303.642 5099.386 14631.01 5951.839 6518.208 
 
22435 26472 21123 23922 2777.327 2777.527 2777.727 2777.927 13886.64 13887.64 13888.64 13889.64 
             CD2 23195 25354 23550 26173 2664.087 3498.756 2801.33 3815.382 13320.44 17493.78 14006.65 19076.91 
 
27503 18146 19021 20161 4329.56 712.1436 1050.419 1491.143 21647.8 3560.718 5252.093 7455.713 
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Day 1 Data: 
134463 138592 135480 130474 34808 17964 17218 18240 17606 18686 18958 20782 
66704 66373 69366 68003 26938 28152 24700 20682 5902 11460 6248 6536 
40105 41099 38014 38864 15148 17236 17736 15950 7730 8072 8188 8766 
20461 22211 20017 21583 10000 9152 11400 10544 15012 15918 16056 17418 
11249 12324 11658 12016 6820 6140 6076 5814 8538 8199 9021 9684 
7018 7318 7457 8262         14628 14409 13260 14811 
7121 7026 6589 8266                 
2423 2097 2113 2032                 
OD 
134752 
 
Cells 
30000 
67612 15000 
39521 7500 
21068 3750 
11812 1875 
7514 937.5 
7251 468.75 
2166 0 
  
0.999411 
Correl 
Coeff 
 
 
OD 
   
Cells 
   
Cells*5 
  Aprotinin D3 34808 17964 17218 18240 7061.436 3195.738 3024.531 3259.08 35307.18 15978.69 15122.66 
Aprotinin D3 26938 28152 24700 20682 5255.271 5533.884 4741.65 3819.519 26276.36 27669.42 23708.25 
Aprotinin D3 15148 17236 17736 15950 2549.466 3028.662 3143.412 2733.525 12747.33 15143.31 15717.06 
            MSCGM D3 10000 9152 11400 10544 1368 1173.384 1689.3 1492.848 6840 5866.92 8446.5 
MSCGM D3 6820 6140 6076 5814 638.19 482.13 467.442 407.313 3190.95 2410.65 2337.21 
MSCGM D3 8410 7646 8738 8179 1003.095 827.757 1078.371 950.0805 5015.475 4138.785 5391.855 
            
            Aprotinin D1 17606 18686 18958 20782 3113.577 3361.437 3423.861 3842.469 15567.89 16807.19 17119.31 
Aprotinin D1 11754 15073 12603 13659 1770.543 2532.254 1965.389 2207.741 8852.715 12661.27 9826.943 
Aprotinin D1 12668 13379 13573 14774 1980.306 2143.481 2188.004 2463.633 9901.53 10717.4 10940.02 
            MSCGM D1 15012 15918 16056 17418 2518.254 2726.181 2757.852 3070.431 12591.27 13630.91 13789.26 
MSCGM D1 14820 15164 14658 16115 2474.19 2553.023 2437.011 2771.278 12370.95 12765.12 12185.06 
MSCGM D1 14628 14409 13260 14811 2430.126 2379.866 2116.17 2472.125 12150.63 11899.33 10580.85 
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Day 1&2 Data: 
98039 91404 102253 111739 22307 18475 17197 22957 15746 15936 15220 17054 
56883 51563 53600 52089 26796 26248 25563 25267 13703 13499 13322 14055 
32239 32041 31852 28214 29112 29635 30028 28179 14888 15453 16964 19287 
19328 18834 16609 17460                 
10983 11132 9687 11363                 
7630 7822 7048 6645                 
8576 8959 7214 7488                 
3777 3417 4671 4497                 
Optical 
Density 
 
100859 
Cells 
 
30000 
53534 15000 
31087 7500 
18058 3750 
10791 1875 
7286 937.5 
8059 468.75 
4091 0 
  
  
0.999467 
correl 
coeff 
 
Day1 OD 
   
Cell 
   
x5 
   Aprotinin 22307 18475 17197 22957 5281.576 4084.843 3685.567 5484.415 26407.88 20424.21 18427.83 27422.07 
MSCGM 15746 15936 15220 17054 3232.576 3291.913 3068.306 3641.064 16162.88 16459.56 15341.53 18205.32 
             
             
             
             Day2 
            Aprotinin 26796 26248 25563 25267 6683.604 6512.407 6298.34 6206.069 33418.02 32562.04 31491.7 31030.35 
Aprotinin 29112 29635 30028 28179 7406.721 7569.969 7692.901 7115.43 37033.6 37849.84 38464.51 35577.15 
MSCGM 13703 13499 13322 14055 2594.547 2530.838 2475.561 2704.477 12972.73 12654.19 12377.8 13522.38 
MSCGM 14888 15453 16964 19287 2964.591 3140.916 3612.988 4338.43 14822.96 15704.58 18064.94 21692.15 
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Day 2 Data: 
X 114486 108143 108981 22396.5 20665.5 22555.5 19738.5 15595 14063 15324 14812 
X 52455 59464 56846 20089 19145 19723 16593 13290 14519 13535 12617 
X 36522 35557 35058 
       
  
X 22044 21279 19318 
       
  
X 16280 15888 15849 
        X 17726 18060 17608 
        X 15889 15572 13764 
        X 10866 10719 11632 
        Error in standard curve column one, excluded from standard curve calculations 
OD Cells 
110536.7 30000 
56255 15000 
35712.33 7500 
20880.33 3750 
16005.67 1875 
17798 937.5 
15075 468.75 
11072.33 0 
  
0.9973 
Correl 
Coeff 
 
OD 
   
Cells 
   
Cells/Suture 
  Aprotinin 
           22396.5 20665.5 22555.5 19738.5 4960.154 4318.421 5019.101 3974.754 24800.77 21592.1 25095.5 19873.77 
20089 19145 19723 16593 4104.695 3754.726 3969.008 2808.623 20523.47 18773.63 19845.04 14043.11 
MSCGM 
  
  
        15595 14063 15324 14812 2438.634 1870.676 2338.167 2148.353 12193.17 9353.38 11690.83 10741.76 
13290 14519 13535 12617 1584.102 2039.729 1674.931 1334.6 7920.509 10198.64 8374.653 6673.002 
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Day 3 Data: 
99010 99327 96887 94801 25866 20605 18959 23455 24202 19899 20893 20113 
56711 57271 53481 54885 10793 10016 9261 9594 28245 25827 26741 29692 
29710 26971 27778 29518 10317 10290 10961 11033 13729 15119 15293 16710 
16843 13533 16639 15019 12915 13888 11606 8370 12426 12382 13359 13131 
11174 9724 9517 9645 10783 10239 9369 10056 25876 25445 25716 31544 
7080 6669 6788 6252 18091 18981 10020 9102 29441 31629 28111 31025 
5103 5136 4772 6347                 
3772 3975 3752 4167                 
 
OD Cells 
97506.25 30000 
55587 15000 
28494.25 7500 
15508.5 3750 
10015 1875 
6697.25 937.5 
5339.5 468.75 
3916.5 0 
  
1 
Correl 
Coeff 
 
  
OD 
   
Cells 
   
Cells*5 
   MSCGM 1 25866 20605 18959 23455 6806 5150 4632 6048 34032 25752 23160 30238 
 
2 10793 10016 9261 9594 2061 1817 1579 1684 10306 9083 7896 8420 
 
3 10317 10290 10961 11033 1912 1903 2114 2137 9558 9515 10572 10684 
 
4 12915 13888 11606 8370 2729 3036 2317 1299 13647 15179 11587 6493 
 
5 10783 10239 9369 10056 2058 1887 1613 1829 10291 9436 8066 9146 
 
6 18091 18981 10020 9102 4359 4639 1818 1529 21794 23195 9090 7646 
              Aprotinin 1 24202 19899 20893 20113 6283 4928 5241 4995 31413 24640 26205 24977 
 
2 28245 25827 26741 29692 7555 6794 7082 8011 37777 33971 35409 40054 
 
3 13729 15119 15293 16710 2986 3423 3478 3924 14928 17116 17390 19621 
 
4 12426 12382 13359 13131 2576 2562 2869 2797 12878 12808 14346 13987 
 
5 25876 25445 25716 31544 6810 6674 6759 8594 34048 33369 33796 42969 
 
6 29441 31629 28111 31025 7932 8621 7513 8430 39659 43103 37566 42152 
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Day 5 Data: 
100766 100855 98178 98562 32060 28648 29051 29894 6036 24605 5540 5967 
58876 53576 52705 62235 14460 16148 16266 14270 14007 13747 14236 14579 
32183 30282 32083 29251 19870 21230 20465 19741 23019 24044 24376 26835 
17759 17862 17742 16593 29176 28396 29249 31125 27678 28341 28267 29301 
11292 11184 11322 9712 29424 26703 27522 26450 14224 14102 13903 15551 
7184 6863 7807 6951 31560 30998 28772 28784 17885 17544 17763 17749 
8334 6782 5852 7001 
 
              
2271 2269 2313 2136                 
 
OD Cells 
99590 30000 
56848 15000 
30950 7500 
17489 3750 
10878 1875 
7201 937.5 
6992 468.75 
2247 0 
  
  
0.998194 
Correl 
Coeff 
 
  
OD 
   
Cells 
   
Cellsx5 
   Aprotinin 1 32060 28648 29051 29894 8379.14 7324.832 7449.359 7709.846 41895.7 36624.16 37246.8 38549.23 
 
2 14460 16148 16266 14270 2940.74 3462.178 3498.794 2881.876 14703.7 17310.89 17493.97 14409.38 
 
3 19870 21230 20465 19741 4612.43 5032.67 4796.285 4572.569 23062.15 25163.35 23981.43 22862.85 
 
4 29176 28396 29249 31125 7487.984 7246.964 7510.541 8090.225 37439.92 36234.82 37552.71 40451.13 
 
5 29424 26703 27522 26450 7564.616 6723.827 6976.898 6645.65 37823.08 33619.14 34884.49 33228.25 
 
6 31560 30998 28772 28784 8224.64 8050.982 7363.148 7366.856 41123.2 40254.91 36815.74 36834.28 
              MSCGM 1 6036 24605 5540 5967 337.724 6075.545 184.46 316.403 1688.62 30377.73 922.3 1582.015 
 
2 14007 13747 14236 14579 2800.763 2720.423 2871.524 2977.511 14003.82 13602.12 14357.62 14887.56 
 
3 23019 24044 24376 26835 5585.471 5902.196 6004.784 6764.615 27927.36 29510.98 30023.92 33823.08 
 
4 27678 28341 28267 29301 7025.102 7229.969 7207.103 7526.609 35125.51 36149.85 36035.52 37633.05 
 
5 14224 14102 13903 15551 2867.816 2830.118 2768.627 3277.859 14339.08 14150.59 13843.14 16389.3 
 
6 17885 17544 17763 17749 3999.065 3893.696 3961.367 3957.041 19995.33 19468.48 19806.84 19785.21 
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Appendix I: Cell Proliferation on Sutures 
  
Cells Ki-67+ Ki-67+Cells 
 
Cells Ki-67+ Avg 
Suture 
Avg 
Day 0 MSCGM1 54 3 0.055556 
 
Aprotinin1 229 8 0.034934 
 
  
87 2 0.022989 0.039272 
 
66 3 0.045455 0.040195 
 
MSCGM2 65 2 0.030769 
 
Aprotinin2 90 6 0.066667 
 
  
64 4 0.0625 0.046635 
 
55 7 0.127273 0.09697 
 
MSCGM3 83 5 0.060241 
 
Aprotinin3 89 8 0.089888 
 
  
70 4 0.057143 0.058692 
 
77 6 0.077922 0.083905 
           Day 1 MSCGM1 90 7 0.077778 
 
Aprotinin1 84 11 0.130952 
 
  
65 1 0.015385 0.046581 
 
72 6 0.083333 0.107143 
 
MSCGM2 78 4 0.051282 
 
Aprotinin2 120 9 0.075 
 
  
109 10 0.091743 0.071513 
 
81 7 0.08642 0.08071 
 
MSCGM3 92 4 0.043478 
 
Aprotinin3 92 9 0.097826 
 
  
77 7 0.090909 0.067194 
 
79 8 0.101266 0.099546 
           
           Day 2 MSCGM1 120 35 0.291667 
 
Aprotinin1 57 9 0.157895 
 
  
96 23 0.239583 0.265625 
 
90 40 0.444444 0.30117 
 
MSCGM2 121 47 0.38843 
 
Aprotinin2 233 102 0.437768 
 
  
87 18 0.206897 0.297663 
 
191 81 0.424084 0.430926 
 
MSCGM3 109 35 0.321101 
 
Aprotinin3 153 90 0.588235 
 
  
101 31 0.306931 0.314016 
 
202 95 0.470297 0.529266 
           
           
           AVG Day 0 Day 1 Day 2 
 
Stdev 
     Aprotinin 7.368969 9.579956 42.04539 
 
2.973411 1.36089 11.44083 
   MSCGM 4.819952 6.176249 29.24347 
 
0.980406 1.332355 2.461545 
    
 
 
 
 
 
